{"_id":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAgN6Yo80JDA","lastupdate":"2024-03-28T00:00:00.000Z","update_date":"2024-03-28T00:00:00.000Z","lastModified":"Oct 24, 2025","active":1,"confidence_score":97,"confidence_score_reason":"markets, external profiles","urlname":"silexion-therapeutics","minimal_profile":null,"status":"Public","fullstatus":"Public on NASDAQ on Aug, 2024;","acquired":0,"hide_reason":null,"hide_reason_data":null,"hide_reasons":[{"id":"8257rxn4P8EFQOmS5hAAauHyYMhhxrA5u6yWX4XUShpybX3AMNo3Y9","reason":"Pending approval - External entity"},{"id":"aOIaOiiqfpA8UMw6VCTh8ueRmkG3lzDy1NGqEOaJbe11OrCzMTCCd6","reason":"The company is a service provider"},{"id":"ddgjKuc3GgH8E5UehSVJviRl471BCajL1plO8HtGoOojy2NivYqQ7x","reason":"Owner asked to delete"},{"id":"EjOKM211H1ira9J63oaGPuUxvr7Oba55TZo3NWsFO5uhbNu7o4x4zD","reason":"The company is not Israeli"},{"id":"J7fQJtnT3GdWWSE3MD8rzaW65LJ4jEIKxSZnneQiReONdZjG3zIqWe","reason":"Owner asked to hide in the meantime"},{"id":"NxlAC3ReFb5ksiYNLp2FnUyluoJzwRCYfcF7xpTZaPM53SdWQ5kv0B","reason":"Pending approval"},{"id":"RhC1tlwXzioK0MfzBII3H2wepEfQOfKVktmdwqeqTJjGi3ZaBWUqZo","reason":"The company is not innovative"},{"id":"S0Ed46vNI6vZYVxLedANWGjas23K6hY0QdsCtiGYL7lshqIEdLV3sA","reason":"The company ceased operations in Israel"},{"id":"VTANq7bEvlsEcPjp0ghelXfShaCosgndONGjgU730aAOxXtaDIF5j3","reason":"This is a product of an existing company"}],"type":"Startup","logokey":"$PlQU4U1YILsMpkmKczHfkwDNK73Itb6Oag72jWqDQttik0VDnaWHLJ.png","name":"Silexion Therapeutics","oneliner":"Development of Innovative Treatments for Pancreatic Cancer","registrar":"514207778","website":"https://silexion.com/","careerspage":"","founded_month":11,"founded_year":2008,"formernames":["Silenseed"],"sociallinks":{"twitter":"","youtube":"","facebook":"","linkedin":"","instagram":""},"social":[],"flattenedsociallinks":null,"apps":{"appstore":"","googleplay":""},"is_claimed_by_owner":1,"employees":"11-50","employees_exact":31,"patent":1,"raised":27650000,"stage":"Public","public_stage":"Public","primary_sector_key":"agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA","primary_sector":"Health Tech & Life Sciences","alternativenames":null,"about":"Silexion Therapeutics is a pioneering developmental stage company dedicated to the development of innovative treatments for pancreatic cancer. \nThe company conducted phase 2 clinical trial with its first generation product which has shown positive efficacy results vs the control of chemotherapy alone. \n\nSilexion’s commitment to pushing the boundaries of therapeutic advancements in the field of oncology, is focused in enhancing its first-generation product (LODERTM) to develop a new formulated product which will improve the clinical efficacy that Silexion observed with its first-generation product against pancreatic cancer.\n\nWith a strong foundation in RNA interference technology, Silexion Therapeutics develops innovative RNA-based therapeutics designed to silence specific genes involved in pancreatic cancer growth and metastasis. By selectively suppressing these genes, it aims to disrupt tumor progression and enhance the therapeutic response.\n","climatetech_description":null,"is_climatetech_relevant":null,"phone":"+97286286005","country":null,"address":{"israeli":[{"id":"2664231a-f483-4678-a80b-837d56266bc9","city":"Modi'in-Maccabim-Re'ut","type":null,"address":"HaMa'ayan Street 2, Modi'in-Maccabim-Re'ut, Israel","placeid":null,"notactive":0,"openeddate":null,"registrarid":null,"firstrdcenter":0,"registrarname":null}],"officesabroad":null},"headquarter_address":null,"district":"Center District","news":[{"id":"zx9fiYSAHTHKrJ7hXkZOtqk9IOtYfa2WfN6YMScvlXowcgBiyDGkgn","date":"Sep 30, 2025","link":"https://finance.yahoo.com/news/silexion-therapeutics-announces-positive-human-124000744.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"cancer research","round":null,"company":"Silexion Therapeutics Corp","layoffs":null,"summary":"Silexion Therapeutics Corp, a clinical-stage biotechnology company, has announced promising preclinical results for its RNA interference therapy, SIL204, targeting KRAS-driven cancers. The therapy demonstrated high inhibition rates (83.5% to 99.7%) across eleven human cancer cell lines with various KRAS mutations, including G12D, G12V, and G12R. This data marks the first evidence of activity in gastric cancer and expands validation in colorectal cancer. SIL204s ability to inhibit a wide range of KRAS mutations positions it as a comprehensive solution for KRAS-driven cancers, potentially addressing a broader patient population than existing therapies. The findings highlight SIL204s potential as a pan-KRAS isoform selective inhibitor, offering significant therapeutic reach.","partners":null,"customers":null,"eventType":null,"investors":null,"confidence":9,"key_topics":["KRAS mutations","cancer therapy","RNA interference","clinical trials","biotechnology"],"date_of_event":"September 30, 2025","product_stage":"clinical trial","investment_date":null,"acquired_company":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Product Stage"],"acquisition_amount":null,"FDA approved/pending approval":"pending approval","AI technology developing/using":"developing","structuredIssuesShow":"#Product Stage","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"6RAKVrDKy5Wb0ggzXS6TvmWIo9hJBVSls1ygeaxJUoU2EUrASwPsc3","news_summary":"Silexion Therapeutics Announces Positive New Human Cell Line Data Confirming Pan-KRAS Activity of SIL204, Demonstrating Up to 99.7% Inhibition and First Evidence in Gastric Cancer","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"kId7OxzKiUH8Gq0LNcWuP5q9tVS8uKtDZI2xe3jhzLdUUkhboZXNsa","date":"Sep 25, 2025","link":"https://finance.yahoo.com/news/silexion-therapeutics-regains-compliance-nasdaq-124500239.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"Nasdaq compliance","round":null,"company":"Silexion Therapeutics Corp","layoffs":null,"summary":"Silexion Therapeutics Corp, a clinical-stage biotechnology company, has successfully regained compliance with Nasdaqs listing requirements, ensuring its continued listing on the Nasdaq Capital Market. The company met the minimum bid price and shareholders equity requirements, reinforcing its financial foundation. Silexion is advancing its RNA interference (RNAi) therapies for KRAS-driven cancers, with plans to initiate Phase 2/3 clinical trials for its lead product candidate, SIL204, in the first half of 2026. The company has demonstrated promising preclinical data and has a strategic CRO collaboration in place. Silexion remains focused on developing transformative therapies for difficult-to-treat cancers.","partners":null,"customers":null,"eventType":null,"investors":null,"confidence":9,"key_topics":["Nasdaq","compliance","RNAi","oncology","clinical trials"],"date_of_event":"September 23, 2025","product_stage":"clinical trial","investment_date":null,"acquired_company":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Product Stage","Public Trading"],"acquisition_amount":null,"FDA approved/pending approval":"pending approval","AI technology developing/using":"developing","structuredIssuesShow":"#Product Stage  #Public Trading","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"z8z8A5ogSQdkhFIW09qSDHOyMmIbObElI7x0gB6s7mD5wHLBjZlDIY","news_summary":"Silexion Therapeutics Regains Compliance with Nasdaq Listing Requirements","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"JaeGbMo5QPWDpP3HVZ5g0vNcFA8ZZIVyymMY8ivOUL9vhL2VoCqlFL","date":"Sep 11, 2025","link":"https://finance.yahoo.com/news/silexion-therapeutics-announces-pricing-6-131700488.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"public offering","round":null,"company":"Silexion Therapeutics Corp","layoffs":null,"summary":"Silexion Therapeutics Corp, a clinical-stage biotech company focused on RNA interference therapies for KRAS-driven cancers, announced a public offering of 1,500,000 ordinary shares and accompanying warrants at $4.00 per share. The offering is expected to raise $6.0 million in gross proceeds, which will be used for advancing pre-clinical studies and general corporate purposes. The offering is facilitated by H.C. Wainwright & Co. as the exclusive placement agent. The offering is made under a registration statement declared effective by the SEC on September 11, 2025, with the closing expected around September 12, 2025.","partners":null,"customers":null,"eventType":"PO","investors":"H.C. Wainwright & Co.","confidence":10,"key_topics":["RNAi therapies","public offering","warrants","SEC registration","placement agent"],"date_of_event":"September 11, 2025","product_stage":"clinical","investment_date":"September 11, 2025","acquired_company":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":"6.0 million","structured_issues":["PIPE/PO"],"acquisition_amount":null,"FDA approved/pending approval":"pending approval","AI technology developing/using":"developing","structuredIssuesShow":"#PIPE/PO","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"L9XWNic3Fu5e5Nic3SZjxPq9irHS61qNwiCsGTju3XLP7Pg4nWbTZi","news_summary":"Silexion Therapeutics Announces Pricing of $6.0 Million Public Offering","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"7hYGaE42CaSx2wi30djXtWxfts6zFy1VaiD6LNI4NmInifiiMoGdQz","date":"Sep 11, 2025","link":"https://finance.yahoo.com/news/silexion-therapeutics-reports-positive-preclinical-110000405.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"preclinical data","round":null,"company":"Silexion Therapeutics Corp","layoffs":null,"summary":"Silexion Therapeutics Corp, a clinical-stage biotechnology company, announced promising preclinical data for its RNA interference (RNAi) therapy, SIL204. The study demonstrated successful drug distribution to key metastatic sites of pancreatic cancer, including the liver, peritoneum, and lung, with measurable reductions in tumor burden. These findings validate Silexions dual-route administration strategy, combining intratumoral and systemic delivery. The company remains on track to initiate Phase 2/3 trials in the first half of 2026, following regulatory submissions in late 2025 and early 2026. This development is significant as it addresses the high mortality rate associated with metastatic pancreatic cancer.","partners":null,"customers":null,"eventType":null,"investors":null,"confidence":10,"key_topics":["RNAi therapies","pancreatic cancer","metastasis","preclinical data","drug distribution"],"date_of_event":"September 11, 2025","product_stage":"preclinical","investment_date":null,"acquired_company":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Product Stage"],"acquisition_amount":null,"FDA approved/pending approval":"pending approval","AI technology developing/using":null,"structuredIssuesShow":"#Product Stage","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"JYbT8Wgz6uVjqRWCuQLj0pVKp6FarLL0B7SYHIKflZ7y2gqKbITq5R","news_summary":"Silexion Therapeutics Reports Positive Preclinical Data Demonstrating SIL204’s Reach and Activity in Major Pancreatic Cancer Metastatic Sites Following Systemic Administration","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"xUCiHzgBn7bmkryvud29pW32CeCx9dmQphZ4an56QHwniw2FQ1GMsp","date":"Sep 4, 2025","link":"https://finance.yahoo.com/news/silexion-therapeutics-announces-selection-contract-132500165.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"clinical trials","round":null,"company":"Silexion Therapeutics Corp","layoffs":null,"summary":"Silexion Therapeutics Corp, a clinical-stage biotechnology company, has announced a strategic partnership with AMS Advanced Medical Services GmbH, a contract research organization (CRO), to support its upcoming Phase 2/3 clinical trials for SIL204. SIL204 is a next-generation siRNA candidate targeting KRAS-driven solid tumor cancers. The partnership aims to bolster Silexions regulatory submissions to the Israel Ministry of Health and the European Union, with trials expected to commence in the first half of 2026. This collaboration follows promising preclinical results, including up to 97% inhibition rates in pancreatic cancer cells. The partnership with AMS, which has extensive oncology expertise, is seen as a critical milestone in advancing SIL204 toward clinical development.","partners":"AMS Advanced Medical Services GmbH","customers":null,"eventType":null,"investors":null,"confidence":9,"key_topics":["RNAi therapies","KRAS-driven cancers","clinical trials","CRO partnership","regulatory submissions"],"date_of_event":"September 4, 2025","product_stage":"clinical trial","investment_date":null,"acquired_company":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Product Stage","Partners"],"acquisition_amount":null,"FDA approved/pending approval":"pending approval","AI technology developing/using":null,"structuredIssuesShow":"#Product Stage  #Partners","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"HfLtmzi0RHxnGLW7SVIMaDlcU5OZSIuDqyKzzyUgtOmJrHnZtsItGS","news_summary":"Silexion Therapeutics Announces Selection of Contract Research Organization to Support Upcoming Phase 2/3 Clinical Trials for SIL204","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"9l16xwFtrkerS7NJdwcdapWlU5eEkQWDuvFdMAbQyHMk2HMmkOUKOD","date":"Sep 2, 2025","link":"https://finance.yahoo.com/news/silexion-therapeutics-present-upcoming-27th-124500681.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"conference","round":null,"company":"Silexion Therapeutics Corp","layoffs":null,"summary":"Silexion Therapeutics Corp, a clinical-stage biotechnology company focused on RNA interference therapies for KRAS-driven cancers, announced its participation in the 27th Annual H.C. Wainwright Global Investment Conference from September 8-10, 2025. The company will present on September 10, 2025, and engage in one-on-one investor meetings. Silexion is advancing its lead product candidate for pancreatic cancer, having shown positive trends in a Phase 2a clinical trial. The event aims to attract investor interest and showcase Silexions innovative oncology treatments.","partners":null,"customers":null,"eventType":null,"investors":null,"confidence":9,"key_topics":["RNAi therapies","KRAS-driven cancers","clinical trial","oncology","investment conference"],"date_of_event":"September 8-10, 2025","product_stage":"clinical trial","investment_date":null,"acquired_company":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Product Stage","Management Changes"],"acquisition_amount":null,"FDA approved/pending approval":"pending approval","AI technology developing/using":"using","structuredIssuesShow":"#Product Stage  #Management Changes","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"YuuDq47hKoo3NPKLQsFVVBrCmKkhzJZf4dvVofmLjbGI5xtjTvUOX5","news_summary":"Silexion Therapeutics to Present at the Upcoming 27th Annual H.C. Wainwright Global Investment Conference","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"ivMla76teyJ0qwwkATiIfo7LauICmx5Fl5EuLhnFIHpXZq5YOrd69s","date":"Aug 12, 2025","link":"https://finance.yahoo.com/news/silexion-therapeutics-reports-second-quarter-120000858.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"cancer research","round":null,"company":"Silexion Therapeutics Corp","layoffs":null,"summary":"Silexion Therapeutics Corp, a clinical-stage biotechnology company, is advancing its SIL204 preclinical program with promising efficacy data across multiple KRAS-driven cancer types. The company has demonstrated significant inhibition rates in pancreatic, colorectal, and lung cancer models. A strategic partnership with Catalent has been established for formulation development and clinical manufacturing. Silexion plans to initiate Phase 2/3 clinical trials in the first half of 2026, focusing on pancreatic cancer. Regulatory submissions are planned for late 2025 and early 2026. The companys financial position is strong, supporting its progress towards clinical trials.","partners":"Catalent","customers":null,"eventType":null,"investors":null,"confidence":10,"key_topics":["preclinical data","KRAS mutations","clinical trials","partnership","RNAi therapies"],"date_of_event":"August 12, 2025","product_stage":"preclinical","investment_date":null,"acquired_company":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Product Stage","Partners"],"acquisition_amount":null,"FDA approved/pending approval":"pending approval","AI technology developing/using":"developing","structuredIssuesShow":"#Product Stage  #Partners","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"ZwSCkvcnjkhoQtZVl4m59DHZpG5qd88v4g5tqaYnooi9vSVXSk6fbc","news_summary":"Silexion Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"nUfbtyLRFgmVYOlzJQs1mxTgI3rpACqfYcJohwjVNwUEzBUOxYSvtf","date":"Aug 1, 2025","link":"https://finance.yahoo.com/news/silexion-therapeutics-announces-exercise-warrants-000000174.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"warrant exercise","round":null,"company":"Silexion Therapeutics Corp","layoffs":null,"summary":"Silexion Therapeutics Corp, a clinical-stage biotech company, announced the exercise of outstanding warrants to purchase 152,106 ordinary shares at a reduced price, generating approximately $1.8 million in gross proceeds. The company plans to use the net proceeds for general corporate purposes. Additionally, Silexion will issue new unregistered warrants for 304,212 shares, exercisable upon shareholder approval of increased authorized shares. H.C. Wainwright & Co. is acting as the exclusive placement agent for this offering. The new warrants were offered in a private placement and are not registered under the 1933 Act. The company intends to file a registration statement with the SEC for the resale of shares issuable upon exercise of the new warrants.","partners":null,"customers":null,"eventType":"PIPE","investors":"H.C. Wainwright & Co.","confidence":10,"key_topics":["RNAi therapies","warrant exercise","KRAS-driven cancers","private placement","working capital"],"date_of_event":"July 31, 2025","product_stage":"clinical trial","investment_date":"July 31, 2025","acquired_company":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":"1.8 million","structured_issues":["PIPE/PO"],"acquisition_amount":null,"FDA approved/pending approval":"pending approval","AI technology developing/using":"using","structuredIssuesShow":"#PIPE/PO","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"zBVIRzlqbEd5MyUIx7pq69JgxsLZCwiYDwwgqDzRKGmP0z3pYs2kKY","news_summary":"Silexion Therapeutics Announces Exercise of Warrants for $1.8 Million Gross Proceeds","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"XXI6vNad32cHrQgMie0diBsIw1b0aKNfHllUOzmbvDI4Cr0MZy0ev7","date":"Jul 31, 2025","link":"https://finance.yahoo.com/news/silexion-therapeutics-announces-preclinical-data-135500968.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"clinical trial","round":null,"company":"Silexion Therapeutics Corp","layoffs":null,"summary":"Silexion Therapeutics Corp, a clinical-stage biotechnology company, has announced groundbreaking preclinical data demonstrating unprecedented inhibition rates in cancer cells. Their RNAi therapy, SIL204, showed up to 97% inhibition in pancreatic cancer cells and nearly 90% in colorectal cancer cells, including efficacy against the KRAS Q61H mutation. These results significantly expand SIL204s potential as a pan-KRAS therapeutic. The company plans to initiate a Phase 2/3 clinical trial in Q2 2026. This development marks a substantial advancement in their research, strengthening SIL204s potential to address unmet needs in treating KRAS-driven cancers.","partners":null,"customers":null,"eventType":null,"investors":null,"confidence":10,"key_topics":["KRAS mutation","cancer therapy","RNAi","clinical trial","efficacy"],"date_of_event":"July 31, 2025","product_stage":"clinical trial","investment_date":null,"acquired_company":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Product Stage"],"acquisition_amount":null,"FDA approved/pending approval":"pending approval","AI technology developing/using":null,"structuredIssuesShow":"#Product Stage","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"fFBf9ugvBhxJOX3LAwkuD55QR8V6dtFDyVVsqefYK3fydBKHQlyV7U","news_summary":"Silexion Therapeutics Announces New Preclinical Data Showing Up to 97% Inhibition of Cancer Cell Growth, Including New Evidence Against New Previously Untested KRAS Mutation","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"3SX3Hf9SAwQLMXuz0ee9YwIuYJ339p9biBzTbHzEk8V4iTyDriXSBu","date":"Jul 16, 2025","link":"https://finance.yahoo.com/news/silexion-therapeutics-announces-1-15-124400363.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"reverse split","round":null,"company":"Silexion Therapeutics Corp","layoffs":null,"summary":"Silexion Therapeutics Corp, a clinical-stage biotechnology company, announced a 1-for-15 reverse share split of its ordinary shares, effective after market close on July 28, 2025. The split aims to help Silexion comply with NASDAQ requirements, enhance its market position, and support strategic growth initiatives. The company is pioneering RNA interference (RNAi) therapies for KRAS-driven cancers and is confident in advancing its innovative therapeutics toward clinical trials. The reverse split is designed to address share price volatility and strengthen Silexions foundation for future growth. Trading on a split-adjusted basis will begin on July 29, 2025.","partners":null,"customers":null,"eventType":"PO","investors":null,"confidence":10,"key_topics":["reverse split","NASDAQ compliance","RNAi therapies","KRAS-driven cancers","clinical trials"],"date_of_event":"July 29, 2025","product_stage":"clinical trial","investment_date":null,"acquired_company":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Public Trading"],"acquisition_amount":null,"FDA approved/pending approval":"pending approval","AI technology developing/using":null,"structuredIssuesShow":"#Public Trading","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"DpfRNfVWcInt1cTHdxMojrALKTL7yAEbLvaRUhY1jxncp38muWZ45b","news_summary":"Silexion Therapeutics Announces 1-for-15 Reverse Share Split","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"cEa2QIaeTBBvirYmWtKjfBRm20ZgYrbtawDauymqrnVg4USlfjEXVq","date":"Jul 9, 2025","link":"https://finance.yahoo.com/news/silexion-therapeutics-announces-positive-results-123000143.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"preclinical data","round":null,"company":"Silexion Therapeutics Corp","layoffs":null,"summary":"Silexion Therapeutics Corp, a clinical-stage biotechnology company, announced positive preclinical data for its RNA interference therapy, SIL204, in treating KRAS-driven lung cancer. The data showed significant efficacy in human lung cancer cell lines, particularly those with KRAS G12D mutations. Silexion is conducting further studies on a new KRAS mutation and plans to release results soon. The company is preparing for a Phase 2/3 clinical trial in Q2 2026. These findings validate SIL204s delivery system and its potential as a versatile therapeutic for KRAS-driven cancers.","partners":null,"customers":null,"eventType":null,"investors":null,"confidence":10,"key_topics":["RNAi therapies","KRAS mutation","lung cancer","SIL204","clinical trial"],"date_of_event":"July 09, 2025","product_stage":"preclinical","investment_date":null,"acquired_company":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Product Stage"],"acquisition_amount":null,"FDA approved/pending approval":"pending approval","AI technology developing/using":null,"structuredIssuesShow":"#Product Stage","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"JWoBRGWZlFd8V8FfOlu8Lfp40NQmdFidudwEo2Tz0k3Cjd7JETMKGm","news_summary":"Silexion Therapeutics Announces Positive Results in Preclinical Study Demonstrating Significant SIL204 Efficacy in Human Lung Cancer Cell Lines","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"Nne1DI1PCpaq10uOmA5Ik7toxRKkio1VK4He6Vj0yRTLsqGwaOrn3I","date":"May 30, 2025","link":"https://finance.yahoo.com/news/silexion-therapeutics-announces-preclinical-results-131021663.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"preclinical data","round":null,"company":"Silexion Therapeutics","layoffs":null,"summary":"Silexion Therapeutics announced promising preclinical data for its RNAi therapeutic candidate, SIL204, which shows efficacy against pancreatic, colorectal, and lung cancer cell lines. The data indicates that SIL204 effectively inhibits the proliferation and metabolic activity of cancer cells with KRAS G12D mutations, expanding its potential to address major KRAS-driven cancers. The company has completed preclinical studies and partnered with Catalent for further development of SIL204. This development is seen as a positive step towards addressing unmet medical needs in cancer treatment.","partners":"Catalent","customers":null,"eventType":null,"investors":null,"confidence":9,"key_topics":["RNAi therapeutic","KRAS mutation","cancer treatment","preclinical studies","SIL204"],"date_of_event":null,"product_stage":"preclinical","investment_date":null,"acquired_company":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Product Stage","Partners"],"acquisition_amount":null,"FDA approved/pending approval":"pending approval","AI technology developing/using":null,"structuredIssuesShow":"#Product Stage  #Partners","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"GR21zqPPJ4xw1BEEdkLcJnRVmjobqAwcGOmIiCIgymkAeUX1Sn4wyb","news_summary":"Silexion Therapeutics announces preclinical results on SIL204","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"AD5WQo8XCFgptrWf2cK0dElnDR0DX33MFmpjDQA1LQ7IWMEj3kNbX9","date":"May 29, 2025","link":"https://finance.yahoo.com/news/silexion-therapeutics-announces-groundbreaking-preclinical-130500063.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"RNAi therapy","round":null,"company":"Silexion Therapeutics Corp","layoffs":null,"summary":"Silexion Therapeutics Corp, a clinical-stage biotechnology company, has announced promising preclinical data for its RNA interference (RNAi) therapeutic candidate, SIL204. The data shows significant anti-tumor activity across major KRAS-driven cancers, including colorectal, lung, and pancreatic cancer cell lines. SIL204 demonstrated a 90% inhibition rate in GP2D colorectal cancer cells, highlighting its potential to address unmet medical needs in KRAS-driven cancers. The company plans to conduct further studies on lung cancer cell lines to expand its therapeutic applications. These findings validate Silexions RNAi approach and suggest potential expansion beyond pancreatic cancer to other high-need cancer indications.","partners":null,"customers":null,"eventType":null,"investors":null,"confidence":10,"key_topics":["RNAi","KRAS","cancer","preclinical","SIL204"],"date_of_event":"May 29, 2025","product_stage":"clinical trial","investment_date":null,"acquired_company":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Product Stage"],"acquisition_amount":null,"FDA approved/pending approval":"pending approval","AI technology developing/using":"developing","structuredIssuesShow":"#Product Stage","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"PSxdrBr3ba4wqTHcU1M7HaON0ukB9wsTJoYYDwHIDPv1Dcuo1VaZpv","news_summary":"Silexion Therapeutics Announces Groundbreaking Preclinical Results: SIL204 Shows Strong Efficacy in Pancreatic, Colorectal, and Lung Cancers","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"24rgywRH5udnjOdUgtHFJiZSmQvhMTBqEiGI3urPoEUnGE6rXsmxB1","date":"May 21, 2025","link":"https://finance.yahoo.com/news/silexion-therapeutics-completes-key-preclinical-124500951.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"oncology","round":null,"company":"Silexion Therapeutics Corp","layoffs":null,"summary":"Silexion Therapeutics Corp, a clinical-stage biotech company, has completed a preclinical study of its RNAi therapeutic candidate, SIL204, which targets KRAS-driven cancers. The study explored SIL204s potential beyond pancreatic cancer, assessing its efficacy in colorectal and lung cancer cell lines. These cancers were chosen due to their high prevalence of KRAS mutations and unmet medical needs. The results, expected soon, could significantly expand Silexions development strategy. The company aims to address the $30 billion treatment market for KRAS-driven tumors, leveraging its RNAi-based approach to overcome challenges faced by small-molecule or antibody therapies.","partners":null,"customers":null,"eventType":null,"investors":null,"confidence":10,"key_topics":["RNAi therapy","KRAS mutations","cancer treatment","preclinical study","oncology innovation"],"date_of_event":"May 21, 2025","product_stage":"clinical trial","investment_date":null,"acquired_company":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Product Stage"],"acquisition_amount":null,"FDA approved/pending approval":"pending approval","AI technology developing/using":null,"structuredIssuesShow":"#Product Stage","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"lCnqOfEXeRPpEBPML9qWeJlWgMaoS8LSx1I4wt0XfOAdgLKbCG2KOQ","news_summary":"Silexion Therapeutics Completes Key Preclinical Studies Exploring SIL204’s Potential Impact on Colorectal and Lung Cancer","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"Wg4DRqvMoRJCXyDH7U857jnZ1HVooUW0D8WCOOldU3bkTNbTNqjo8m","date":"May 13, 2025","link":"https://finance.yahoo.com/news/silexion-therapeutics-reports-first-quarter-204500919.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"RNAi therapies","round":null,"company":"Silexion Therapeutics Corp","layoffs":null,"summary":"Silexion Therapeutics Corp, a clinical-stage biotech company, has made significant advancements in its SIL204 program, demonstrating efficacy in reducing primary tumors and metastases in preclinical models. The company raised over $9 million in Q1 2025 through a public offering and warrant exercises, strengthening its financial position. Silexion announced a strategic collaboration with Catalent for formulation development and clinical manufacturing of SIL204. The company plans to initiate clinical trials in the first half of 2026, focusing on a dual-route development strategy to address KRAS-driven cancers. These developments position Silexion for continued growth and advancement in oncology therapeutics.","partners":"Catalent","customers":null,"eventType":"PO","investors":null,"confidence":10,"key_topics":["preclinical data","financial results","strategic collaboration","development strategy","clinical trials"],"date_of_event":"May 13, 2025","product_stage":"clinical trial","investment_date":"Q1 2025","acquired_company":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":"9 million","structured_issues":["Product Stage","Investment","PIPE/PO","Partners"],"acquisition_amount":null,"FDA approved/pending approval":"pending approval","AI technology developing/using":"developing","structuredIssuesShow":"#Product Stage  #Investment  #PIPE/PO  #Partners","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"FfnAXl9hK7fz2W7Buyd0dUEavlLpPih8V40Ie9GDwiCdpm2FlpCgeP","news_summary":"Silexion Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"OaCGCQWAnJvKO5pPVSBdCIfeAGmhIGarWTDlKBdhjLcp1eNm6wOG1x","date":"Apr 23, 2025","link":"https://finance.yahoo.com/news/silexion-therapeutics-announces-collaboration-global-132000062.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"collaboration","round":null,"company":"Silexion Therapeutics Corp","layoffs":null,"summary":"Silexion Therapeutics Corp, a clinical-stage biotechnology company, has announced a strategic collaboration with Catalent to advance the development of its RNA interference (RNAi) therapy, SIL204, targeting KRAS-driven cancers. The partnership will focus on optimizing the delivery formulations of SIL204, leveraging Catalents expertise in complex formulation development. This collaboration is a significant step forward for Silexion, following promising preclinical results, as it aims to initiate human clinical trials in 2026. The collaboration will also support regulatory submissions in Israel and the EU.","partners":"Catalent","customers":null,"eventType":null,"investors":null,"confidence":10,"key_topics":["RNAi therapies","KRAS mutations","clinical trials","drug formulation","cancer treatment"],"date_of_event":"April 23, 2025","product_stage":"clinical trial","investment_date":null,"acquired_company":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Product Stage","Partners"],"acquisition_amount":null,"FDA approved/pending approval":"pending approval","AI technology developing/using":null,"structuredIssuesShow":"#Product Stage  #Partners","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"T0dvOVHIzuCiCXSbv7xnda5JhZQm8DvjRgG9Ib3G2lzDzvljiKZgZo","news_summary":"Silexion Therapeutics Announces Collaboration with Global Therapeutics Leader Catalent on Advanced siRNA Formulation Development & Clinical Manufacturing Activities","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"m8K9f0Jdqp9aEhbTFfopD0BF55pzavNZTEeldDSfj9UzpNlG5yHkmy","date":"Mar 28, 2025","link":"https://finance.yahoo.com/news/silexion-therapeutics-unveils-innovative-expanded-123000831.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"clinical development","round":null,"company":"Silexion Therapeutics Corp","layoffs":null,"summary":"Silexion Therapeutics Corp, a clinical-stage biotechnology company, announced an expanded development plan for its siRNA candidate, SIL204, targeting KRAS-driven pancreatic cancer. The strategy involves a dual-route administration approach, integrating systemic and intratumoral delivery to address both primary tumors and metastases. This decision follows promising preclinical data showing significant tumor growth inhibition. The company plans to initiate human trials in the first half of 2026, with regulatory submissions to the Israel Ministry of Health and the European Union. The expanded plan builds on previous clinical results and aims to provide a comprehensive treatment solution for KRAS-driven cancers.","partners":null,"customers":null,"eventType":null,"investors":null,"confidence":10,"key_topics":["RNAi therapies","KRAS-driven cancers","clinical trials","preclinical data","treatment strategy"],"date_of_event":"March 28, 2025","product_stage":"clinical trial","investment_date":null,"acquired_company":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Product Stage"],"acquisition_amount":null,"FDA approved/pending approval":"pending approval","AI technology developing/using":null,"structuredIssuesShow":"#Product Stage","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"OEg61FcwAoAKFceiluR7Qi7t51S55nQ3ismGH6rmQNl6DxeUQDaO0L","news_summary":"Silexion Therapeutics Unveils Innovative Expanded Development Plan for SIL204 Based on Recent Groundbreaking Preclinical Data","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"QlzZWzNlk5a95suUB0TXxhIebD5q0V9R53tCc0w5io2ogDoNY0knXX","date":"Mar 21, 2025","link":"https://finance.yahoo.com/news/silexion-therapeutics-announces-completion-innovative-123000352.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"development plan","round":null,"company":"Silexion Therapeutics Corp","layoffs":null,"summary":"Silexion Therapeutics Corp, a clinical-stage biotechnology company, announced an expanded development plan for its siRNA candidate, SIL204, targeting KRAS-driven cancers. The plan will be presented at the 2025 NeauxCancer Conference. The company aims to leverage recent preclinical data to advance SIL204 toward clinical development, focusing on pancreatic cancer. Silexions first-generation product, LODER™, has shown promising results in a Phase 2 clinical trial for non-resectable pancreatic cancer. The company is committed to innovating RNA interference therapies to improve outcomes for patients with challenging cancers.","partners":null,"customers":null,"eventType":null,"investors":null,"confidence":10,"key_topics":["RNAi therapies","KRAS-driven cancers","preclinical data","development plan","conference presentation"],"date_of_event":"March 21, 2025","product_stage":"clinical-stage","investment_date":null,"acquired_company":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Product Stage"],"acquisition_amount":null,"FDA approved/pending approval":"pending approval","AI technology developing/using":"developing","structuredIssuesShow":"#Product Stage","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"RLuHWHhYc0i906ieVbOjOHzMKRp8KXvb6batFk2H4b9c4xygBue9nv","news_summary":"Silexion Therapeutics Announces Completion of Innovative Expanded Development Plan for SIL204 which will be unveiled at the 2025 NeauxCancer Conference","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"CNUVSgbdHmQy3uSVCoCSRTQEHG2w16Tfq5na99KV4tic3uM36pM6S1","date":"Mar 20, 2025","link":"https://www.globenewswire.com/news-release/2025/03/21/3047043/0/en/Silexion-Therapeutics-Announces-Completion-of-Innovative-Expanded-Development-Plan-for-SIL204-which-will-be-unveiled-at-the-2025-NeauxCancer-Conference.html","source":"www.globenewswire.com","visible":1,"analysis":{"tags":"RNAi therapies","round":null,"company":"Silexion Therapeutics Corp","layoffs":null,"summary":"Silexion Therapeutics Corp, a clinical-stage biotechnology company, announced an expanded development plan for its siRNA candidate, SIL204, targeting KRAS-driven cancers. The plan builds on promising preclinical data and aims to maximize SIL204s potential across various delivery approaches. Silexion will present this plan at the NeauxCancer 2025 Conference. The company is focused on advancing SIL204 toward clinical development, particularly for pancreatic cancer. Silexions first-generation product, LODER™, has shown promising results in a Phase 2 clinical trial for non-resectable pancreatic cancer. The company is committed to innovating RNA interference therapies to treat solid tumors driven by KRAS mutations.","partners":null,"customers":null,"eventType":null,"investors":null,"confidence":9,"key_topics":["RNAi therapies","KRAS mutations","oncology","preclinical data","strategic plan"],"date_of_event":"March 21, 2025","product_stage":"clinical-stage","investment_date":null,"acquired_company":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Product Stage"],"acquisition_amount":null,"FDA approved/pending approval":"pending approval","AI technology developing/using":"developing","structuredIssuesShow":"#Product Stage","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"aeZLKOj1aE163asjkZqacDoKwquD1GRpM5WEfFU5Ab1ktzCPWZzOia","news_summary":"Silexion Therapeutics Announces Completion of Innovative Expanded Development Plan for SIL204 which will be unveiled at the 2025 NeauxCancer Conference","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"NP9dFGrV5X63DeqOwrvJhb02G7PEHMdZU2gFo9cvqnoRWZlP0wjVFf","date":"Mar 18, 2025","link":"https://finance.yahoo.com/news/silexion-therapeutics-reports-full-2024-202900568.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"biotechnology","round":null,"company":"Silexion Therapeutics Corp","layoffs":null,"summary":"Silexion Therapeutics Corp, a clinical-stage biotechnology company, has made significant advancements in its RNA interference therapies targeting KRAS-driven cancers. The company reported promising preclinical results for its second-generation candidate, SIL204, and plans to initiate Phase 2/3 clinical trials by 2026. Silexion completed a merger with Moringa Acquisition Corp, becoming publicly traded on Nasdaq, which enhances its access to capital. The company raised approximately $7.9 million in net proceeds through various financial transactions, strengthening its financial position. Additionally, Silexion appointed Prof. Amnon Peled to its Board of Directors, further bolstering its expertise in cancer therapeutics.","partners":null,"customers":null,"eventType":"SPAC","investors":null,"confidence":10,"key_topics":["RNAi therapies","KRAS-driven cancers","clinical trials","funding","Nasdaq listing"],"date_of_event":"March 18, 2025","product_stage":"clinical","investment_date":"2024","acquired_company":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":"7.9 million","structured_issues":["Public Trading","Investment","Management Changes","Product Stage"],"acquisition_amount":null,"FDA approved/pending approval":"pending approval","AI technology developing/using":"developing","structuredIssuesShow":"#Public Trading  #Investment  #Management Changes  #Product Stage","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"Ps5Ki58GxAZDZiSAVYvLCNGCpm4Bl43wwVJNm1lRQBONRCDHEJqUTu","news_summary":"Silexion Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"H5WJrgxZ9S58oAiix6nrMt1ct9Gu0gZZTsqWCL3IsXQU60CwxJ4aES","date":"Mar 17, 2025","link":"https://finance.yahoo.com/news/pesg-report-silexion-therapeutics-breakthrough-121500022.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"oncology","round":null,"company":"Silexion Therapeutics","layoffs":null,"summary":"Silexion Therapeutics, a clinical-stage biotechnology company, has made significant strides with its SIL204 therapeutic candidate, showcasing transformative preclinical data in the fight against KRAS-driven cancers, particularly pancreatic cancer. The therapy demonstrated remarkable efficacy in reducing tumor cell bioluminescence and suppressing metastatic spread. The precision oncology market is rapidly growing, with Silexions RNAi technology targeting challenging KRAS mutations, which are prevalent in pancreatic cancers. The market context highlights the value of innovative oncology assets, as evidenced by recent high-profile acquisitions. Wall Street maintains a buy rating for Silexion, with a $9 price target, reflecting a significant premium over current prices.","partners":null,"customers":null,"eventType":null,"investors":null,"confidence":10,"key_topics":["oncology","KRAS mutations","RNAi technology","precision medicine","acquisitions"],"date_of_event":"March 17, 2025","product_stage":"clinical","investment_date":null,"acquired_company":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Product Stage"],"acquisition_amount":null,"FDA approved/pending approval":"pending approval","AI technology developing/using":"using","structuredIssuesShow":"#Product Stage","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"g8g1PD6CcJ93RHYnAvNO3wlPA3Gzq3vJQ5Cu8DpGx7LJwbz5F6KwF1","news_summary":"PESG Report: Silexion Therapeutics’ Breakthrough Data Shows SIL204's impact on both Primary Tumors & Metastasis – Signaling a Potential Paradigm Shift in Cancer Treatment","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"Ailfrkjont2wrBVi7oWyRjYwJyRa1adQfPXLfhqbv1AXeGGo0qUDa6","date":"Mar 5, 2025","link":"https://finance.yahoo.com/news/silexion-therapeutics-reports-groundbreaking-positive-133000248.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"clinical trial","round":null,"company":"Silexion Therapeutics Corp","layoffs":null,"summary":"Silexion Therapeutics Corp, a clinical-stage biotechnology company, has announced promising results from its latest study on SIL204, an RNA interference (RNAi) therapy for KRAS-driven pancreatic cancers. The study demonstrated that subcutaneously administered SIL204 significantly reduces both primary tumor growth and metastatic spread in clinically relevant orthotopic models. These findings validate SIL204s efficacy in a more realistic setting, where human pancreatic tumor cells are implanted directly into the pancreas. The therapy showed robust activity across multiple pancreatic cancer cell lines, including those with KRAS mutations, and demonstrated a significant reduction in metastatic spread to secondary organs. This advancement marks a significant step forward in the treatment of pancreatic cancer.","partners":null,"customers":null,"eventType":null,"investors":null,"confidence":10,"key_topics":["RNAi therapies","pancreatic cancer","tumor reduction","metastasis","KRAS mutation"],"date_of_event":"March 05, 2025","product_stage":"clinical trial","investment_date":null,"acquired_company":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Product Stage"],"acquisition_amount":null,"FDA approved/pending approval":"pending approval","AI technology developing/using":"developing","structuredIssuesShow":"#Product Stage","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"Kfd1loRKxuBHhUzNISCu6panKJr6mD8roLZc2wd50xtY9DPYxOJUSN","news_summary":"Silexion Therapeutics Reports Groundbreaking Positive Initial Data from Systemic Administration of SIL204 in Orthotopic Pancreatic Cancer Models","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"mhEus35iymWvnkbFLLiBahm3qAJQABKNldnsmet9BXmpRdh85x7Cbc","date":"Mar 3, 2025","link":"https://finance.yahoo.com/news/pesg-industry-anticipation-rises-silexion-133000441.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"clinical trial","round":null,"company":"Silexion Therapeutics","layoffs":null,"summary":"Silexion Therapeutics is approaching a significant milestone with its orthotopic pancreatic cancer model data, which could validate its RNAi therapys efficacy against metastatic disease. The company recently completed an initial study evaluating SIL-204, a next-generation RNAi therapy targeting KRAS-driven cancers. The study aims to demonstrate the therapys ability to reduce tumor growth and inhibit metastasis in pancreatic cancer models. Maxim Group maintains a strong buy rating and a $9 price target for Silexion, citing the companys growing clinical trajectory. If the upcoming data readout is positive, it could be a pivotal breakthrough for Silexion, differentiating its approach from existing KRAS-targeting therapies.","partners":null,"customers":null,"eventType":null,"investors":"Maxim Group","confidence":10,"key_topics":["pancreatic cancer","RNAi therapy","KRAS mutations","clinical trial","tumor growth"],"date_of_event":"March 03, 2025","product_stage":"clinical trial","investment_date":null,"acquired_company":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Product Stage"],"acquisition_amount":null,"FDA approved/pending approval":"pending approval","AI technology developing/using":"using","structuredIssuesShow":"#Product Stage","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"HZ79SFPLStlVy8tVATgyziYL9cVor10GFQU8K2GWdb5xeks8qGKxTP","news_summary":"PESG Industry Update: Anticipation Rises as Silexion Therapeutics Approaches a Key Preclinical Data That Could Be Transformational","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"y5OpsrVhZnyoURltElJbnXjZ3xk9TjZO2gqzSxti8VuGn7jsxHwv2u","date":"Feb 25, 2025","link":"https://finance.yahoo.com/news/silexion-therapeutics-announces-completion-initial-133000462.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"clinical trial","round":null,"company":"Silexion Therapeutics Corp","layoffs":null,"summary":"Silexion Therapeutics Corp, a clinical-stage biotechnology company, has completed the data collection phase of its initial study evaluating SIL-204 in orthotopic pancreatic cancer models. This study marks a significant milestone as it is the first systematic evaluation of SIL-204 administered subcutaneously in clinically relevant pancreatic cancer models. The study focused on SIL-204s ability to reduce primary tumor growth and metastatic spread. The use of orthotopic models, which better reflect human pancreatic cancer biology, provides more translational value than standard subcutaneous xenograft models. The company is analyzing the data and expects to report results soon, which could broaden SIL-204s therapeutic applications.","partners":null,"customers":null,"eventType":null,"investors":null,"confidence":10,"key_topics":["RNAi therapies","pancreatic cancer","tumor growth","metastatic spread","systemic administration"],"date_of_event":"February 25, 2025","product_stage":"clinical trial","investment_date":null,"acquired_company":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Product Stage"],"acquisition_amount":null,"FDA approved/pending approval":"pending approval","AI technology developing/using":"developing","structuredIssuesShow":"#Product Stage","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"AqXmDaxCMaEqdlu5nC8VZjpUBxXdFzvaMydibnJwcwjGAATdpS1pvI","news_summary":"Silexion Therapeutics Announces Completion of Initial Study in Orthotopic Pancreatic Cancer Models Evaluating Systemic Administration of SIL-204","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"z0RDlrBCHp7fg3gHEr6mHjXM1P6zkcTbOEAe6sHTZxIjT3iWwwEMmD","date":"Jan 29, 2025","link":"https://finance.yahoo.com/news/silexion-therapeutics-announces-exercise-warrants-223000478.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"warrant exercise","round":null,"company":"Silexion Therapeutics Corp","layoffs":null,"summary":"Silexion Therapeutics Corp, a clinical-stage biotech company, announced the exercise of outstanding warrants to purchase 2,221,523 ordinary shares, generating approximately $3.3 million in gross proceeds. The company plans to use the funds as working capital for general corporate purposes. H.C. Wainwright & Co. acted as the exclusive placement agent for the offering. In addition to the exercised warrants, Silexion will issue new unregistered warrants with an exercise price of $1.50 per share, valid for 24 months. The company will file a registration statement with the SEC for the resale of shares issuable upon exercise of these new warrants.","partners":"H.C. Wainwright & Co.","customers":null,"eventType":"PIPE","investors":"H.C. Wainwright & Co.","confidence":9,"key_topics":["warrants","RNAi therapies","KRAS cancers","fundraising","biotech"],"date_of_event":"January 29, 2025","product_stage":"clinical trial","investment_date":"January 29, 2025","acquired_company":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":"3.3 million","structured_issues":["PIPE/PO"],"acquisition_amount":null,"FDA approved/pending approval":"pending approval","AI technology developing/using":"developing","structuredIssuesShow":"#PIPE/PO","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"GWYE03uYM74WmEzFD427BsZ1mRUvIegy1vpkPHyGl3n1aZduKYAD41","news_summary":"Silexion Therapeutics Announces Exercise of Warrants for $3.3 Million Gross Proceeds","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"LQImYo1pUYSRWLoRZFm7Ie6zmu4wyspBMRAdsdjaYY62j2R1CPDP6T","date":"Jan 29, 2025","link":"https://finance.yahoo.com/news/pesg-report-silexion-therapeutics-systemic-145900692.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"precision oncology","round":null,"company":"Silexion Therapeutics","layoffs":null,"summary":"Silexion Therapeutics has reported significant preclinical data showing a 50% reduction in tumor growth using their RNAi platform, SIL-204, for KRAS-driven cancers. This breakthrough positions Silexion as a strong contender in the precision oncology market, which is currently experiencing a surge in multi-billion dollar acquisitions. The company has received a strong buy rating from Maxim Group, with a $9 price target, reflecting confidence in its innovative approach. Silexions strategic partnership with Evonik for advanced formulation and its advancement toward clinical trials highlight its potential in addressing challenging cancer mutations. The industry is increasingly investing in precision medicine, and Silexions differentiated RNAi approach offers broader applicability compared to traditional small molecule inhibitors.","partners":"Evonik","customers":null,"eventType":null,"investors":null,"confidence":9,"key_topics":["RNAi therapeutics","KRAS mutations","oncology market","preclinical data","strategic partnerships"],"date_of_event":"January 29, 2025","product_stage":"preclinical","investment_date":null,"acquired_company":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Product Stage","Partners"],"acquisition_amount":null,"FDA approved/pending approval":"pending approval","AI technology developing/using":null,"structuredIssuesShow":"#Product Stage  #Partners","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"UGUPY8DLiRaYPRPEb15mGknilM8DhFQovtkVKZQ46fQHTbgOfDZo7J","news_summary":"PESG Report: Silexion Therapeutics’ Systemic Delivery Breakthrough Positions Company as Rising Star in The Multi-Billion Dollar Precision Oncology Market","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"ymDQ7o9eAdVhXqdHTJ703jsLUhgVQCHXrGFDZcYWTMmNMVIvwCqowz","date":"Jan 28, 2025","link":"https://finance.yahoo.com/news/silexion-therapeutics-reports-strong-tumor-132900078.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"preclinical data","round":null,"company":"Silexion Therapeutics Corp","layoffs":null,"summary":"Silexion Therapeutics Corp, a clinical-stage biotechnology company, has announced promising preclinical data for its siRNA therapeutic candidate, SIL-204. The data demonstrates significant tumor growth reduction in orthotopic pancreatic cancer models, validating systemic administration as an effective delivery approach. SIL-204 targets KRAS mutations and has shown potential in addressing aggressive cancers. Further studies are planned to evaluate its impact on metastases. The company is optimistic about expanding its treatment strategy for KRAS-driven cancers and plans to announce details of its development plan soon.","partners":null,"customers":null,"eventType":null,"investors":null,"confidence":9,"key_topics":["RNAi therapies","tumor growth","KRAS mutations","preclinical data","systemic administration"],"date_of_event":"January 28, 2025","product_stage":"preclinical","investment_date":null,"acquired_company":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Product Stage"],"acquisition_amount":null,"FDA approved/pending approval":"pending approval","AI technology developing/using":null,"structuredIssuesShow":"#Product Stage","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"biNHHbqnaVcfhsXlGBKlkIJOs9nQ6479tEyjVWSZ9zperfsAFOlecr","news_summary":"Silexion Therapeutics Reports Strong Tumor Growth Reduction from Systemic Administration of SIL-204 in Preclinical Pancreatic Cancer Models","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"jDWR97Qth3zRv1QXQ2UiYVo91CCR7NJXeny1qAXSfyFLeDqgQH8i8N","date":"Jan 16, 2025","link":"https://finance.yahoo.com/news/silexion-therapeutics-announces-pricing-5-010000057.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"Public Offering","round":null,"company":"Silexion Therapeutics Corp","layoffs":null,"summary":"Silexion Therapeutics Corp, a clinical-stage biotech company, announced a public offering of its ordinary shares and warrants, aiming to raise approximately $5.0 million. The offering is priced at $1.35 per share, with warrants exercisable immediately and expiring in five years. The proceeds will be used to advance pre-clinical studies and for general corporate purposes. H.C. Wainwright & Co. is the exclusive placement agent for the offering. Silexion is focused on developing RNA interference therapies for KRAS-driven cancers, with promising results from its first-generation product, LODER™, in a Phase 2 trial for pancreatic cancer. The company is also advancing its next-generation siRNA candidate, SIL-204, in preclinical studies.","partners":null,"customers":null,"eventType":"PO","investors":"H.C. Wainwright & Co.","confidence":10,"key_topics":["RNAi therapies","KRAS-driven cancers","public offering","clinical-stage","oncology"],"date_of_event":"January 15, 2025","product_stage":"clinical trial","investment_date":"January 15, 2025","acquired_company":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":"5.0 million","structured_issues":["Public Trading"],"acquisition_amount":null,"FDA approved/pending approval":"pending approval","AI technology developing/using":"developing","structuredIssuesShow":"#Public Trading","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"hcteo9VIvjkFhuua8FcBhdH4lnjVmL9vHrcMM6KOeS5SF8KdcZyurd","news_summary":"Silexion Therapeutics Announces Pricing of $5.0 Million Public Offering","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"RT9s9yiVVQFXy9Ymc5VxP3h0gFVupiDDIjHmhccWmOJBN9gmPi3ofh","date":"Jan 16, 2025","link":"https://finance.yahoo.com/news/pesg-market-silexion-therapeutics-sil-160400748.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"oncology","round":null,"company":"Silexion Therapeutics","layoffs":null,"summary":"Silexion Therapeutics, a clinical-stage biotech company, is advancing RNA interference therapies for KRAS-driven cancers. The company has reported promising preclinical data for its siRNA candidate, SIL-204, which enhances the efficacy of first-line chemotherapy agents in treating pancreatic cancer. SIL-204 targets a broader spectrum of KRAS mutations, building on the success of Silexions first-generation LODER™ platform. With toxicology studies and Phase 2/3 trials planned, Silexion is poised to advance its candidate into the clinic. The company also announced a $5 million public offering to support its preclinical and clinical efforts, positioning itself as a key innovator in precision oncology.","partners":null,"customers":null,"eventType":"PO","investors":null,"confidence":9,"key_topics":["KRAS mutations","RNAi therapies","pancreatic cancer","clinical trials","public offering"],"date_of_event":"January 16, 2025","product_stage":"clinical trial","investment_date":"January 16, 2025","acquired_company":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":"5 million","structured_issues":["Product Stage","PIPE/PO"],"acquisition_amount":null,"FDA approved/pending approval":"pending approval","AI technology developing/using":null,"structuredIssuesShow":"#Product Stage  #PIPE/PO","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"o5Yw6IDoprVK1BQBS4WxUEVsKyr53nyT0J18YsHiuxrUCBgxSKA6RA","news_summary":"PESG Market Update: Silexion Therapeutics’ SIL-204 Shows Groundbreaking Synergy in Preclinical Data, Boosting Hope for KRAS-Driven Cancer Treatments","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"6EgVXt6iYubdcdSpRhMUMYbyVQYFcrO5dqibWCY00g3Bm3ejXveKj1","date":"Jan 15, 2025","link":"https://finance.yahoo.com/news/silexion-therapeutics-announces-additional-promising-210100343.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"preclinical results","round":null,"company":"Silexion Therapeutics Corp","layoffs":null,"summary":"Silexion Therapeutics Corp, a clinical-stage biotech company, announced promising preclinical results for its second-generation siRNA candidate, SIL-204. The study demonstrated significant synergistic activity when SIL-204 was combined with chemotherapy agents 5-fluorouracil, irinotecan, and gemcitabine in treating KRAS-mutated pancreatic cancer. These findings suggest that SIL-204 could enhance the efficacy of standard chemotherapy treatments, potentially revolutionizing the treatment landscape for pancreatic and other KRAS-mutated cancers. The results build on previous successes with Silexions first-generation product, LODER™, which showed improved survival rates in Phase 2 trials. The company aims to address unmet needs in oncology by enhancing existing treatment regimens.","partners":null,"customers":null,"eventType":null,"investors":null,"confidence":9,"key_topics":["synergy","chemotherapy","KRAS mutations","pancreatic cancer","preclinical"],"date_of_event":"January 15, 2025","product_stage":"clinical trial","investment_date":null,"acquired_company":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Product Stage"],"acquisition_amount":null,"FDA approved/pending approval":"pending approval","AI technology developing/using":null,"structuredIssuesShow":"#Product Stage","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"n7A1hI8FanM4jSa3lAMMX8HNh1LMZkEpy110Z1xb7rVPiScPvIEm8D","news_summary":"Silexion Therapeutics Announces Additional Promising Preclinical Data for SIL-204, Demonstrating Impressive Synergy with First-Line Pancreatic Cancer Chemotherapies","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"WknqMwfCRZ2XQ3S9cDbxsk8ClEnWLFhOHxZ1mdJmIid81zGUjVnYmk","date":"Jan 13, 2025","link":"https://finance.yahoo.com/news/silexion-therapeutics-present-sil-204-125000076.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"presentation","company":"Silexion Therapeutics Corp","layoffs":null,"summary":"Silexion Therapeutics Corp, a clinical-stage biotech company, is set to present data on its SIL-204 siRNA therapy at the 2025 ASCO Gastrointestinal Cancers Symposium in San Francisco. The presentation will focus on the treatment of cancers with specific KRAS mutations. Silexions innovative RNA interference therapies aim to treat solid tumors driven by KRAS mutations, a common oncogenic driver in human cancers. The companys first-generation product, LODER™, has shown promising results in Phase 2 trials for pancreatic cancer, and SIL-204 is designed to target a broader range of KRAS mutations. The presentation is expected to highlight Silexions commitment to advancing cancer treatment and improving patient outcomes.","partners":null,"customers":null,"investors":null,"confidence":10,"key_topics":["RNAi therapies","KRAS mutations","cancer treatment","clinical trials","oncology"],"date_of_event":"January 23-25, 2025","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":[],"acquisition_amount":null,"entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"4vkVEfJGoS7mesNyxFjxaqYrbWpBRhS2imlCF9S8lIL8Gj2AJHCZmu","news_summary":"Silexion Therapeutics to Present SIL-204 Data in KRAS-Driven Pancreatic Cancer at the 2025 ASCO Gastrointestinal Cancers Symposium","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"qUdykpP7hvLgrGxsPQLlZ65v2G4nOCoLNPJBHFhJGIZfQAjHRLoPr3","date":"Dec 18, 2024","link":"https://finance.yahoo.com/news/silexion-therapeutics-evonik-collaborate-sirna-113518101.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"collaboration","company":"Silexion Therapeutics","layoffs":null,"summary":"Silexion Therapeutics has announced its collaboration with Evonik to develop an advanced siRNA formulation aimed at improving cancer treatment efficacy. The partnership utilizes Evoniks biodegradable PLGA microparticle formulation for Silexions siRNA candidate, SIL-204. This formulation has shown high efficacy in preclinical models targeting KRAS mutations, a significant challenge in oncology. The collaboration aims to deliver sustained-release RNAi therapy for more effective cancer treatment. This partnership is expected to positively impact Silexions growth by enhancing its therapeutic offerings.","partners":["Evonik"],"customers":null,"investors":null,"confidence":10,"key_topics":["siRNA","cancer","formulation","collaboration","KRAS"],"date_of_event":"December 18, 2024","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Partners"],"acquisition_amount":null,"structuredIssuesShow":"#Partners","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"e1lugNtymC34ponYkmt5qzp5kR2wPmOhZ3O4magYhQ3Xt18SUJp1Jj","news_summary":"Silexion Therapeutics, Evonik collaborate on siRNA formulation development","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"1rYTbeDqV9YLPfTkFpE3njy9IHh2vzfo8aAxTU1TOVgbHc4yOJVK00","date":"Dec 17, 2024","link":"https://finance.yahoo.com/news/pesg-releases-market-silexion-therapeutics-143600317.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"precision oncology","company":"Silexion Therapeutics","layoffs":null,"summary":"Silexion Therapeutics, a clinical-stage biotechnology company, is making significant strides in precision oncology by focusing on KRAS-driven cancers. In collaboration with Evonik, Silexion has developed a long-acting PLGA microparticle formulation for its siRNA candidate, SIL-204. This innovation targets KRAS mutations, which are prevalent in pancreatic, colorectal, and lung cancers. The collaboration marks a strategic milestone for Silexion, positioning it as a strong contender in the rapidly evolving precision oncology space. The announcement comes amid rising M&A activity in the oncology sector, highlighting the demand for innovative cancer therapies.","partners":"Evonik","customers":null,"investors":null,"confidence":10,"key_topics":["KRAS mutations","oncology","RNAi therapies","collaboration","cancer treatment"],"date_of_event":"December 17, 2024","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Partners"],"acquisition_amount":null,"structuredIssuesShow":"#Partners","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"0y2a4QwgsTOO3ZmNw5pjhJikZ1MRObJwfkiFQ70R6DBoj5I16wyajM","news_summary":"PESG Releases Market Update: Silexion Therapeutics Advances KRAS-Targeting Therapies with New Collaboration As Industry Demand for Precision Oncology Solutions Rises","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"4K9SebRIlIVDXBDCYQy6phlcMSQoY74tnf7dWioI0FH0WT5ahL9PUc","date":"Dec 17, 2024","link":"https://finance.yahoo.com/news/silexion-therapeutics-collaborates-evonik-advanced-113000040.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"collaboration","company":"Silexion Therapeutics Corp","layoffs":null,"summary":"Silexion Therapeutics Corp, a clinical-stage biotech company, has announced its collaboration with Evonik Corporation to develop a long-acting siRNA PLGA microparticle formulation aimed at treating KRAS-mutated cancers. This partnership leverages Evoniks expertise in biodegradable formulations to enhance the efficacy of Silexions next-generation siRNA candidate, SIL-204. The formulation has shown promising results in preclinical models, indicating potential for improved cancer treatment. Silexions focus remains on advancing RNA interference therapies to target challenging genetic drivers in oncology, with the goal of improving outcomes for patients with difficult-to-treat cancers.","partners":"Evonik Corporation","customers":null,"investors":null,"confidence":10,"key_topics":["RNAi therapies","KRAS mutations","oncology","collaboration","preclinical studies"],"date_of_event":"December 17, 2024","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Partners"],"acquisition_amount":null,"structuredIssuesShow":"#Partners","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"JMjQJdLewZOcnF8AwuxEZlltgHcdoxchrsS6B0n11vy5dDAoq2WyPo","news_summary":"Silexion Therapeutics collaborates with Evonik on advanced siRNA Formulation Development","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"zbtWpdgI3d0wOQZeZrE52Hsk2FQCeNslUtBbN2Vb2NY7Q7PM78l0oX","date":"Dec 10, 2024","link":"https://finance.yahoo.com/news/silexion-therapeutics-appoints-renowned-cancer-133000436.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"management changes","company":"Silexion Therapeutics Corp","layoffs":null,"summary":"Silexion Therapeutics Corp, a clinical-stage biotech company focused on RNA interference therapies for KRAS-driven cancers, announced the appointment of Prof. Amnon Peled as an independent director to its Board of Directors. Prof. Peled, a renowned expert in cancer biology and stem cell research, will also serve on several key committees. His appointment is expected to bolster Silexions strategic and scientific capabilities as it advances its pipeline of RNAi-based therapies. The addition of Prof. Peled aligns with Silexions mission to address unmet needs in oncology and ensures compliance with Nasdaqs listing requirements. This move is seen as growth-positive for the company, reinforcing its commitment to innovation and excellence in cancer therapeutics.","partners":null,"customers":null,"investors":null,"confidence":10,"key_topics":["RNAi therapies","KRAS mutations","cancer treatment","board appointment","scientific expertise"],"date_of_event":"December 10, 2024","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Management Changes"],"acquisition_amount":null,"structuredIssuesShow":"#Management Changes","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"gHUeXGURRi3WA8jgkC6xpz5YHScLNJkTF5N16c2Zr2pB5MQTRAh5WL","news_summary":"Silexion Therapeutics Appoints Renowned Cancer Therapeutics Expert Prof. Amnon Peled to Board of Directors","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"VxQFKAerHnkLNbMgwaPEueM1poVDSj7W0ODbFwzrs0xSHc90zMPcfY","date":"Nov 22, 2024","link":"https://finance.yahoo.com/news/silexion-therapeutics-announces-1-9-213000776.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"reverse split","company":"Silexion Therapeutics Corp","layoffs":null,"summary":"Silexion Therapeutics Corp announced a 1-for-9 reverse share split of its ordinary shares, effective after market close on November 27, 2024. Trading on a split-adjusted basis will begin on November 29, 2024. This move aims to help Silexion comply with NASDAQ requirements, maintain its listing, and support strategic growth initiatives. The reverse split is expected to enhance the companys market position and address short-term share price volatility. Shareholders will receive rounded-up whole shares for any fractional shares. The adjustment aligns with Silexions commitment to advancing its clinical programs and delivering value to shareholders.","partners":null,"customers":null,"investors":null,"confidence":10,"key_topics":["reverse split","NASDAQ compliance","shareholders","market position","growth initiatives"],"date_of_event":"November 29, 2024","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Public Trading"],"acquisition_amount":null,"structuredIssuesShow":"#Public Trading","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"19uAJ9oqMwsp6hlbikEKoVGn3LQMKxAxsjLIErvDPATtaiD6Jb9umz","news_summary":"Silexion Therapeutics Announces 1-for-9 Reverse Share Split","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"hjNpTATdt9779EvFCsoCou9PLTMnNXuHnP5o8AmXfQiV5j1a11pWrq","date":"Nov 20, 2024","link":"https://finance.yahoo.com/news/silexion-therapeutics-present-noble-capital-133000505.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"conference","company":"Silexion Therapeutics Corp","layoffs":null,"summary":"Silexion Therapeutics Corp, a clinical-stage biotech company focused on RNA interference therapies for KRAS-driven cancers, announced its participation in the Noble Capital Markets 20th Annual Emerging Growth Equity Conference on December 3-4, 2024, in Boca Raton, Florida. CEO Ilan Hadar will present on the companys innovative approach to pancreatic cancer treatment. Silexions first-generation product, LODER™, has shown promising results in Phase 2 trials for non-resectable pancreatic cancer, and the company is advancing its next-generation siRNA candidate, SIL-204. The management team will be available for one-on-one meetings with interested investors. The event highlights Silexions commitment to advancing oncology therapeutics and improving patient outcomes.","partners":[],"customers":[],"investors":[],"confidence":10,"key_topics":["RNAi therapies","KRAS mutations","oncology","pancreatic cancer","clinical trials"],"date_of_event":"December 3-4, 2024","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":[],"acquisition_amount":null,"entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"VhdpZVtOMG1v198QWaEDim1GXL1pkIPwfrvHXykdiS0Q5QudHV5fRR","news_summary":"Silexion Therapeutics to Present at the Noble Capital Markets 20th Annual Emerging Growth Equity Conference","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"BYdohEVZNMKEAEgrdT0kOroj0r8i176jA1ABS7ZNHo4NxdzsAOnxgb","date":"Nov 14, 2024","link":"https://finance.yahoo.com/news/silexion-therapeutics-reports-third-quarter-133000217.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"clinical advancements","company":"Silexion Therapeutics Corp.","layoffs":null,"summary":"Silexion Therapeutics Corp., a clinical-stage biotech company, has made significant advancements in its clinical and preclinical programs targeting KRAS-driven cancers. The company completed a merger with Moringa Acquisition Corp on August 15, 2024, and is now publicly traded on Nasdaq under the ticker SLXN. This strategic move provides Silexion with greater access to capital to advance its clinical pipeline. The companys first-generation candidate, LODER™, has shown promise in clinical settings for non-resectable pancreatic cancer, with a 56% objective response rate in Phase 2 trials. Silexion is also preparing its next-generation candidate, SIL-204, for clinical trials targeting locally advanced pancreatic cancer and exploring applications in colorectal cancer. These developments underscore Silexions potential to deliver groundbreaking treatments for hard-to-treat cancers.","partners":null,"customers":null,"investors":"Moringa Acquisition Corp","confidence":10,"key_topics":["KRAS-driven cancers","clinical trials","RNAi therapies","oncology","Nasdaq listing"],"date_of_event":"August 15, 2024","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Public Trading","Acquisition"],"acquisition_amount":null,"structuredIssuesShow":"#Public Trading  #Acquisition","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"9NuELC3QTRIgO8cvsrXLxhmM8DR0DJuvlBq2SJMfbVq2nCOQjIrWn7","news_summary":"Silexion Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"ujP9u3EOemyrKTx5eko08lrutCQEOTSg3J3IzkzvHRv2QQXThlga4Q","date":"Oct 9, 2024","link":"https://finance.yahoo.com/news/silexion-therapeutics-present-2024-maxim-213500347.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"conference participation","company":"Silexion Therapeutics Corp.","layoffs":null,"summary":"Silexion Therapeutics Corp., a clinical-stage biotech company focused on developing RNA interference therapies for KRAS-driven cancers, announced its participation in the 2024 Maxim Healthcare Virtual Summit. The summit will take place from October 15 to 17, 2024, and will feature a fireside chat with Silexions CEO, Ilan Hadar, and Chief Scientific Officer, Dr. Mitchell Shirvan. The company will also be available for one-on-one meetings with interested investors. Silexion is advancing its RNAi therapies, including its first-generation product, LODER™, and next-generation candidate, SIL-204, which show promise in treating difficult-to-treat cancers.","partners":[],"customers":[],"investors":[],"confidence":10,"key_topics":["RNAi therapies","KRAS-driven cancers","Maxim Healthcare Summit","oncology","innovation"],"date_of_event":"October 15, 2024","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":[],"acquisition_amount":null,"entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"kNVLNuGsAZHPFUOSniD0Z34BIbc50qhEnw9VMfg9EuigYuND3geZWn","news_summary":"Silexion Therapeutics to Present at 2024 Maxim Healthcare Virtual Summit","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"zTIBzT7uiERdXTVJVaf45YxBLQtQpbLJlh6ZRoSGUtyK8uRvlNi4Fp","date":"Oct 1, 2024","link":"https://www.businesswire.com/news/home/20241001946039/en/","source":"www.businesswire.com","visible":1,"analysis":null,"sentiment":null,"analysisId":"meSTp28phSOSAGJPDndjElIisCOgYDDqLF2UEQj5XmUiJgeeIGikWP","news_summary":"Silexion Therapeutics Reports Breakthroughs From SIL-204 Preclinical Studies","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"none"},{"id":"M4kwhIVwIKKsx8Kteyu6eMxzS7sypyyw7IpfLd5lN3mMn4gxYIbeC0","date":"Sep 24, 2024","link":"https://www.businesswire.com/news/home/20240924477763/en/","source":"www.businesswire.com","visible":1,"analysis":null,"sentiment":null,"analysisId":"jFZU6PEZhn7C7H0wHmz9e6dyiVguUJEWIwqJNzdVJv2ze7L5IpCPkB","news_summary":"Silexion Therapeutics Announces Significant New Data from Phase 2 Trial of LODER™ in Non-Resectable Pancreatic Cancer","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"none"},{"id":"yB5wxQCzCymJ4bkiRyc74ftDUVU4gJhNRei3TVCbntF8yPwU2N5B4G","date":"Sep 9, 2024","link":"https://www.businesswire.com/news/home/20240909510939/en/","source":"www.businesswire.com","visible":1,"analysis":null,"sentiment":null,"analysisId":"9D2oTu6RMajvHV0YixLsktlxPMmtsqf669vkIL9phTUMs25ul94hY9","news_summary":"PESG Releases Report on Silexion Therapeutics: Pioneering RNAi Technology in the Fight Against KRAS-Driven Cancers","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"none"},{"id":"7WdMrVIOosouaDQzKUPooX1mZkkbKSiIAXjA233nJJLye5UDAsWK5F","date":"Sep 3, 2024","link":"https://finance.yahoo.com/news/silexion-therapeutics-present-h-c-200500965.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"conference","company":"Silexion Therapeutics, Inc.","layoffs":null,"summary":"Silexion Therapeutics, Inc., a clinical-stage oncology-focused biotechnology company, announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference from September 9-11, 2024, at the Lotte New York Palace Hotel in New York. The company will present its advancements, including a Phase 2a clinical trial for its lead product candidate targeting KRAS-mutated solid tumors. Silexions management will be available for one-on-one meetings with interested investors. The presentation will be available on demand starting September 9, 2024, and a replay will be accessible on the companys website for 90 days.","partners":null,"customers":null,"investors":["H.C. Wainwright"],"confidence":10,"key_topics":["conference","presentation","oncology","clinical trial","KRAS"],"date_of_event":"2024-09-09","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Investment"],"acquisition_amount":null,"structuredIssuesShow":"#Investment","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"Zvut7TkV7wKJCVgZw3ddvVWXWM0mF72Kti4JXWmAYKvShrwvLkvcuT","news_summary":"Silexion Therapeutics to Present at the H.C. Wainright 26th Annual Global Investment Conference","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"1ROMO5Z5ISgPvAkyQfDFHtOW6wwKe71DJT4DAtBDZeko9awngv4PK2","date":"Aug 15, 2024","link":"https://www.globenewswire.com/news-release/2024/08/15/2931245/0/en/Silexion-Therapeutics-Ltd-and-Moringa-Acquisition-Corp-Announce-Closing-of-their-Business-Combination.html","source":"www.globenewswire.com","visible":1,"analysis":{"tags":"Business Combination","company":"Silexion Therapeutics","layoffs":null,"summary":"Silexion Therapeutics, a clinical-stage oncology-focused biotechnology company, has completed a business combination with Moringa Acquisition Corp, a publicly-traded special purpose acquisition company. The combined entity, now named Silexion Therapeutics Corp, will begin trading on Nasdaq under the tickers SLXN and SLXNW on August 16, 2024. This transaction is expected to provide Silexion with greater financial and strategic flexibility to advance its mission of developing novel siRNA therapies for cancer treatment. The business combination was approved by Moringas shareholders on August 6, 2024.","partners":null,"customers":null,"investors":"Moringa Acquisition Corp","confidence":10,"key_topics":["Business Combination","Nasdaq Listing","Oncology","Clinical Trials","Strategic Flexibility"],"date_of_event":"2024-08-15","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Acquired-by","Public Trading"],"acquisition_amount":null,"structuredIssuesShow":"#Acquired-by  #Public Trading","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"CCeY6AqU57TCTTeW1w6nZGdHPA5VfnbcH2mEEg0kxbRseRZOpTWfNP","news_summary":"Silexion Therapeutics Ltd. and Moringa Acquisition Corp Announce Closing of their Business Combination","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"0DqcMelGjb6lVvm3ckByLolsdlZ8YPv5mdo4d8Igkn6A4YdKF4Lsz9","date":"Aug 15, 2024","link":"https://finance.yahoo.com/news/silexion-therapeutics-ltd-moringa-acquisition-200500930.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"Business Combination","company":"Silexion Therapeutics Corp","layoffs":null,"summary":"Silexion Therapeutics, a clinical-stage oncology-focused biotechnology company, has completed its business combination with Moringa Acquisition Corp, a special purpose acquisition company. The combined entity, now named Silexion Therapeutics Corp, will start trading on Nasdaq under the tickers SLXN and SLXNW from August 16, 2024. This merger is expected to provide Silexion with enhanced financial and strategic flexibility to advance its mission of developing novel siRNA therapies for cancer treatment. The business combination was approved by Moringas shareholders on August 6, 2024, and involved the redemption of 427,297 Class A ordinary shares by Moringa’s public shareholders.","partners":["Moringa Acquisition Corp"],"customers":null,"investors":["Moringa Acquisition Corp"],"confidence":10,"key_topics":["Nasdaq","oncology","business combination","clinical trial","KRAS oncogene"],"date_of_event":"2024-08-15","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Acquired-by","Public Trading"],"acquisition_amount":null,"structuredIssuesShow":"#Acquired-by  #Public Trading","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"qgiByPFvcIZ9rZPojjgDmyUf6nobLmPLoyj1agyzA5VxEmzalOdAtg","news_summary":"Silexion Therapeutics Ltd. and Moringa Acquisition Corp Announce Closing of their Business Combination","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"l0PPWRqk3f5Ci4qxkw6DaJ1JnotBUsygPWssH1EL17owl79SQ0OZtL","date":"Feb 21, 2024","link":"https://www.globenewswire.com/news-release/2024/02/22/2833670/0/en/Silexion-a-Clinical-Stage-Oncology-Focused-Biotechnology-Company-to-Become-Publicly-Traded-Via-Business-Combination-with-Moringa-Acquisition-Corp.html","source":"www.globenewswire.com","visible":1,"analysis":{"tags":"Acquisition, Public Trading","company":"Silexion Ltd.","layoffs":"Not mentioned","summary":"Moringa Acquisition Corp has announced a business combination agreement with Silexion Ltd., a clinical-stage, oncology-focused biotechnology company. The agreement will result in Silexion becoming publicly listed on the Nasdaq. The business combination provides for Silexion’s pre-transaction equity value to be $62.5 million, based on a $10 share price. The business combination, which has been unanimously approved by the boards of directors of Silexion and Moringa, is expected to close in the third quarter of 2024.","partners":"Not mentioned","customers":"Not mentioned","investors":"Moringa Acquisition Corp","confidence":9,"key_topics":"Business Combination, Clinical Trials, Oncology, RNA Therapeutics, Shareholders","date_of_event":"Feb. 22, 2024","valuation_amount":"$62.5 million","impact_on_company":"growth-positive","investment_amount":"Not mentioned","structured_issues":"Acquisition, Public Trading","acquisition_amount":"Not mentioned","structuredIssuesShow":"#Acquisition, Public Trading","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"AVY4msGxzfy9keZZRzAVzGcXNkt8k1UQzv6Pzy7QVzjtEc7bv3pgoK","news_summary":"Silexion, a Clinical-Stage, Oncology-Focused Biotechnology Company, to Become Publicly Traded Via Business Combination with Moringa Acquisition Corp","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"c72d78e4-aedc-4205-b9c9-6a21b644deb4","date":"Oct 5, 2021","link":"https://www.calcalistech.com/ctech/articles/0,7340,L-3919028,00.html","source":"www.calcalistech.com","visible":1,"analysis":{"tags":"investment, partnership","company":"Silenseed","layoffs":null,"summary":"Silenseed, a clinical-stage biopharmaceutical company, has signed a Joint Venture Agreement with Guangzhou Sino-Israel Bio-Industry Investment Fund LLP (GIBF) to create a jointly-owned Chinese subsidiary. GIBF will develop, market, and sell Silenseeds products in China. The agreement includes a $7.8 million investment by GIBF for a 49% equity interest in the Silenseed Chinese subsidiary. The investment will provide liquidity for Silenseeds Phase III clinical trial and operations in pancreatic cancer. Silenseed is focused on developing RNA interference-based cancer drugs and delivery systems.","partners":"Guangzhou Sino-Israel Bio-Industry Investment Fund LLP (GIBF)","customers":null,"investors":"Guangzhou Sino-Israel Bio-Industry Investment Fund LLP (GIBF)","confidence":9,"key_topics":["Silenseed","Joint Venture Agreement","Guangzhou Sino-Israel Bio-Industry Investment Fund","Chinese subsidiary","Pancreatic cancer"],"date_of_event":"2021-10-05","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":"$7.8 million","structured_issues":["Investment","Partners"],"acquisition_amount":null,"structuredIssuesShow":"#Investment  #Partners","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"PiqGwBU2ei7FhqzZmdcf5ANa8xZphH3tPEx9mLTjLZnYvX7ee7TSTH","news_summary":"Silenseed signs $7.8 million agreement with GIBF to create Chinese subsidiary","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"2e821813-193e-4ce7-bb99-f947280cff3c","date":"Aug 1, 2017","link":"http://nocamels.com/2017/08/israeli-biomed-firm-silenseed-raises-10-million/","source":"nocamels.com","visible":1,"analysis":{"tags":"investment","company":"Silenseed","layoffs":null,"summary":"Silenseed, an Israeli clinical-stage bio-pharmaceutical company, is raising $10 million to fund the second phase of a trial for developing a pancreatic cancer treatment. The funding was recently approved by the FDA. Silenseed utilizes targeted RNA interference (RNAi) to develop cancer drugs and delivery systems.","partners":null,"customers":null,"investors":null,"confidence":9,"key_topics":["Silenseed","clinical-stage bio-pharmaceutical company","cancer therapies","raising $10 million","pancreatic cancer treatment"],"date_of_event":"August 1, 2017","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":"$10 million","structured_issues":["Investment"],"acquisition_amount":null,"structuredIssuesShow":"#Investment","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"b3zw6qEoOVVYyaZ3Bfc3gOgi00jekH1XXMMRNl49eb2emnbHN237yN","news_summary":"Israeli Biomed Firm Silenseed Raises $10M","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"ce79cb38-a6e8-4dc0-9e35-b493493b965e","date":"Jul 30, 2017","link":"https://en.globes.co.il/en/article-silenseed-phase-ii-pancreatic-cancer-drug-trial-to-begin-1001199102","source":"en.globes.co.il","visible":1,"analysis":{"tags":"drug development","company":"Silenseed","layoffs":null,"summary":"Silenseed, an Israeli drug development company, is set to begin a Phase II multicenter trial for its pancreatic cancer treatment. The company has raised $10 million, mainly from private investors, to help conduct the trial. Silenseeds drug is based on siRNA technology, which prevents the decoding of certain proteins from a gene called KRAS, creating a mutation that becomes a cancerous cell. The company has developed a unique delivery system using a polymer implant to protect the drug and release it gradually. Silenseed had considered an IPO on Nasdaq but decided to raise funds conventionally before attempting a larger IPO.","partners":null,"customers":null,"investors":"private investors","confidence":9,"key_topics":["Phase II trial","siRNA technology","delivery system","Nasdaq IPO","pancreatic cancer treatment"],"date_of_event":"July 30, 2017","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":"$10 million","structured_issues":["Investment"],"acquisition_amount":null,"structuredIssuesShow":"#Investment","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"PmLSdyChXsv8hoqT0IC25lwefvyDe8lvef1LgfXJcmGDIjwL17sH16","news_summary":"Silenseed Phase II pancreatic cancer drug trial to begin","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"dbda4ba0-2706-422a-83e2-67edd5f63ccf","date":"Nov 10, 2015","link":"http://www.nasdaq.com/article/silenced-rna-biotech-silenseed-withdraws-35-million-ipo-cm541263","source":"www.nasdaq.com","visible":1,"analysis":{"entityGrowthIconPath":"none;"},"sentiment":null,"analysisId":"GmaeemPQhDFtvgVPHh1llXQpK7gZbLUoWZuwSV4a40ksw68ttraJNR","news_summary":"Silenced: RNA biotech Silenseed withdraws $35 million IPO","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"fae3a404-f934-4a8e-bfd4-5021d91d3674","date":"Jun 13, 2014","link":"http://www.nasdaq.com/article/cancer-biotech-silenseed-files-for-a-35-million-ipo-cm361757","source":"www.nasdaq.com","visible":1,"analysis":{"entityGrowthIconPath":"none;"},"sentiment":null,"analysisId":"5jwoJB7xNa33aaDEE3KI1CY1GBheyL2gEYPXP81HgYIHcpiVZJs5AH","news_summary":"Cancer biotech Silenseed files for a $35 million IPO","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"}],"newsNumber":51,"techcommunityinvolvement":null,"mediagallery":[{"id":"bbd27f4e-36ce-4513-af8a-c335e1d96c66","timestamp":"2020-01-29 09:28:49.000000","resources_type":2,"resources_title":"","resources_file_name":"5gNIiX7KRWA","alt":"","imageurl":"https://img.youtube.com/vi/5gNIiX7KRWA/0.jpg","url":"http://youtu.be/5gNIiX7KRWA"},{"id":"577c1c08-3e4c-4be1-9f74-e27a0f817d05","timestamp":"2019-04-28 07:24:06.000000","resources_type":2,"resources_title":"Silenseed - Targeted Therapies for Solid Tumors","resources_file_name":"6qgk9g4yC1c","alt":"Silenseed - Targeted Therapies for Solid Tumors logo","imageurl":"https://img.youtube.com/vi/6qgk9g4yC1c/0.jpg","url":"http://youtu.be/6qgk9g4yC1c"}],"tags":["drug-discovery","biological-therapy","cancer","oncology","drug-delivery","pharmaceuticals","cancer-therapy"],"classificationIDs":["agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4NvztpMKDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Iety_cIDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Kv1pZ8LDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEJDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA"],"technologysuccessstory":null,"usecases":[],"businessmodels":["B2B"],"productstage":"Clinical Trial","products":["LODER","SIL-103"],"geomarkets":["United States","China"],"targetmarkets":[],"marketcapital":10361692,"marketcapitaldate":"2025-11-01T14:05:42.000Z","funding":{"investors":1,"lastfunding":"$6M","totalrounds":6,"fundingstage":"Public","totalfunding":"$27.65M","publicinvestors":1,"lastpublicfunding":6000000,"totalpublicrounds":6,"totalpublicfunding":27650000},"team":[{"name":"Amotz Shemi, PhD","email":"ashemi@gmail.com","phone":"","gender":"Male","userid":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICAgN6x0vcIDA","bounced":true,"claimed":1,"founder":1,"urlname":"amotz-shemi-phd","visible":1,"memberid":"agxzfmlsbGlzdHNpdGVyFwsSCk5ld19NZW1iZXIYgICA8bK0wwkM","position":"Co-Founder & CEO","last_name":"Shemi, PhD","claimtoken":"e27e7c3bb4cf5f18648c24a62946b62c06e8cf2639f9050b32df982a7b5b9b16","first_name":"Amotz","picturekey":null,"claimeddate":"2014-07-29","linkedinurl":"https://www.linkedin.com/in/amotz-shemi-05916545","unsubscribed":false,"is_activeuser":1,"additionalemail":"amotz@silenseed.com","claimedemaildate":null,"initials":"AS","pictureurl":"/assets/empty-state.svg","linkedin-display":"flex","teammembertagclass":"none","teammembertagcontent":"","channelId":"","visibilityClassName":"","visibilityTooltip":""}],"description_edited":1,"tag_line_edited":1,"sector":"Pharmaceuticals","sectorverify":{"id":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICAgPGylJ0IDA","fullname":"Natalia Golczar"},"biverify":{"id":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICAgMGgoMMJDA","fullname":"Yanina Wainscheinker"},"biverifydate":"2020-05-06T00:00:00.000Z","crunchbaseid":"silenseed","lastupdator":"Yanina Wainscheinker","lastupdator_email":"yanina.wainscheinker@sncentral.org","creator":"Rebecca Mack","creator_email":"rebeccamack26@gmail.com","createdate":"2014-07-29T00:00:00.000Z","biverification":"Yanina Wainscheinker","sectorverification":"Natalia Golczar","affiliatedOrganizations":null,"timeline":[{"id":"9xPfYUoUUCAAX6BWz2h6ts8UrKblOIJEJQt4mnfUIV7AGN0WY2NtOq","date":"Sep 2025","amount":"Undisclosed","source":"https://www.tipranks.com/news/company-announcements/silexion-therapeutics-announces-6m-public-offering#google_vignette","ticker":"SLXN","eventtype":"POEvent","valuation":"Undisclosed","investment":[],"capitalraised":"$6M","stockexchange":"NASDAQ","eventvisibility":"Public","amountvisibility":null,"fundingvisibility":null,"stockexchange_key":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgOCIutD_CQw","stockexchange_logokey":"$AU2PTNC6m8YQhSAZinm36kCeLZigl0lwDvuFvOK4ns8LMZtmlmhlUB","style":"","hiddenCompanyTooltip":"","stockexchange_logourl":"https://storage.googleapis.com/clean-finder-353810/$AU2PTNC6m8YQhSAZinm36kCeLZigl0lwDvuFvOK4ns8LMZtmlmhlUB","exit_label":"","po_label":"Public Offering","acquireddesc":"Was acquired by","sectionname":"Public Offerings & Exit","amountnumber":null,"capitalraisednumber":6000000,"valuationnumber":null},{"id":"lALX6gpmNteKlie7QZEc6xotFcAZQ3PJvDIgjl1OzCREa2NTob1qus","date":"Jan 2025","amount":"$3.3M","source":"https://www.globenewswire.com/news-release/2025/01/29/3017648/0/en/Silexion-Therapeutics-Announces-Exercise-of-Warrants-for-3-3-Million-Gross-Proceeds.html","eventtype":"FundingRoundEvent","investment":[],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"PIPE","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","sectionname":"Private Equity Funding","amountnumber":3300000,"capitalraised":"Undisclosed","valuation":"Undisclosed"},{"id":"Y6gHLMgs4DT5Uzf9jsBAohaUCMwrGw9xjtG5goxFbv4sGlx85NyZCa","date":"Aug 2024","amount":"Undisclosed","source":"https://www.globenewswire.com/news-release/2024/08/15/2931245/0/en/Silexion-Therapeutics-Ltd-and-Moringa-Acquisition-Corp-Announce-Closing-of-their-Business-Combination.html","ticker":"SLXN","eventtype":"SpacEvent","valuation":"Undisclosed","investment":[],"capitalraised":"Undisclosed","stockexchange":"NASDAQ","eventvisibility":"Public","amountvisibility":null,"fundingvisibility":null,"stockexchange_key":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgOCIutD_CQw","acquiredcompany_spac":"Moringa Acquisition Corp","stockexchange_logokey":"$AU2PTNC6m8YQhSAZinm36kCeLZigl0lwDvuFvOK4ns8LMZtmlmhlUB","acquiredcompany_spac_id":"jMHxZavYLrxVUxYYBB6QnAeVmnqi3yNQbv7xZBx51gHnRxw93L6Ph5","acquiredcompany_spac_type":"Multinational","acquiredcompany_spac_hidden":true,"acquiredcompany_spac_fullurl":"/mnc_page/moringa-acquisition-corp","acquiredcompany_spac_logokey":"$212EvMfP9e1cXfqQiWj4bR3fCbKPoAcxCMR2DSCYMaj01VANjJEkf7.png","acquiredcompany_spac_urlname":"/mnc_page/moringa-acquisition-corp","acquiredcompany_spac_homepage":"https://www.moringaac.com/","style":"","hiddenCompanyTooltip":"","stockexchange_logourl":"https://storage.googleapis.com/clean-finder-353810/$AU2PTNC6m8YQhSAZinm36kCeLZigl0lwDvuFvOK4ns8LMZtmlmhlUB","acquiredcompany_spac_logourl":"https://storage.googleapis.com/clean-finder-353810/$212EvMfP9e1cXfqQiWj4bR3fCbKPoAcxCMR2DSCYMaj01VANjJEkf7.png","exit_label":"EXIT","po_label":"Initial Public Offering","acquireddesc":"Was acquired by","sectionname":"Public Offerings & Exit","amountnumber":null,"capitalraisednumber":0,"valuationnumber":0},{"id":"KyxWG62jhxMOt1IWqJBqz1YXhZbR2JdX7gdSp0UgL66LmLblxyKlKM","date":"Oct 2015","amount":"$2.35M","source":"pitchbook","eventtype":"FundingRoundEvent","investment":[{"name":"Esperante Ventures","type":"Investor","amount":null,"hidden":false,"country":"Netherlands","fullurl":"/investor_page/esperante-ventures","logokey":"$ecItkh2OXcAwDfS5y9qbsBxjwnoKV9ipUEAeAZBUo7tCOH2acuvhiC","tagline":"","urlname":"/investor_page/esperante-ventures","isisraeli":0,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgOD4u4ShCgw","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"rDORLUF6UUD5v51moaPghp0eufQNOQBmUFnIUzFGec0pfrbWV5YhU2","fundingsubtype":"VC and Private Equity","investorislead":1,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":1,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$ecItkh2OXcAwDfS5y9qbsBxjwnoKV9ipUEAeAZBUo7tCOH2acuvhiC","leadcaption":"Lead ","followupcaption":"Follow on "}],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"Undisclosed Round","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","sectionname":"Private Equity Funding","amountnumber":2350000,"capitalraised":"Undisclosed","valuation":"Undisclosed"},{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgODO_sKOCAw","date":"Apr 2014","amount":"$10M","source":"https://www.esperanteventures.com/portfolio/silenseed/","eventtype":"FundingRoundEvent","investment":[{"name":"Esperante Ventures","type":"Investor","amount":0,"hidden":false,"country":"Netherlands","fullurl":"/investor_page/esperante-ventures","logokey":"$ecItkh2OXcAwDfS5y9qbsBxjwnoKV9ipUEAeAZBUo7tCOH2acuvhiC","tagline":"","urlname":"/investor_page/esperante-ventures","isisraeli":0,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgOD4u4ShCgw","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"aca945b4-f09e-46b9-bfca-32d296b3ca67","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$ecItkh2OXcAwDfS5y9qbsBxjwnoKV9ipUEAeAZBUo7tCOH2acuvhiC","leadcaption":"","followupcaption":""}],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"Seed","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","sectionname":"Private Equity Funding","amountnumber":10000000,"capitalraised":"Undisclosed","valuation":"Undisclosed"},{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgOCutMbTCAw","date":"Sep 2009","amount":"$6M","source":"https://www.sec.gov/Archives/edgar/data/1602634/000117891314002077/exhibit_10-6.htm","eventtype":"GrantEvent","granttype":1,"investment":[],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":null,"isjointventuregrant":0,"fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","sectionname":"Non-Equity Funding","isgrant":true,"isicoevent":false,"amountnumber":6000000,"capitalraised":"Undisclosed","valuation":"Undisclosed"}],"investmentstage":[],"exits":[],"investments":[],"portfolio":[],"funds":[],"founded":"11/2008","databases":[],"sharedspaces":[],"utilities":[],"contributors":[],"employeesworldwide":"","fundingtype":"Startup","parsedName":"Silexion Therapeutics","logourl":"https://storage.googleapis.com/clean-finder-353810/$PlQU4U1YILsMpkmKczHfkwDNK73Itb6Oag72jWqDQttik0VDnaWHLJ.png","oglogourl":"https://storage.googleapis.com/clean-finder-353810/$PlQU4U1YILsMpkmKczHfkwDNK73Itb6Oag72jWqDQttik0VDnaWHLJ.png","seoabout":"Silexion Therapeutics is a pioneering developmental stage company dedicated to the development of innovative treatments for pancreatic cancer. \nThe company...","seoTitle":"Israeli Startup","solutions":[],"teamMembersNumber":1,"primarySector":"Health Tech & Life Sciences","primary-sector-display":"block","classifications":[{"depth":0,"name":"Sector","queryString":"sectorclassification=undefined","classificationName":"sectorclassification"},{"depth":1,"name":"Health Tech & Life Sciences","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA","classificationName":"sectorclassification"},{"depth":2,"name":"Pharma & Medical Biotechnology","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA","classificationName":"sectorclassification"},{"depth":3,"name":"Drugs Discovery & Development","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Iety_cIDA","classificationName":"sectorclassification"},{"depth":0,"name":"Core Technology","queryString":"coretechnology=undefined","classificationName":"coretechnology"},{"depth":1,"name":"Biologicals","queryString":"coretechnology=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEJDA","classificationName":"coretechnology"},{"depth":2,"name":"Genes","queryString":"coretechnology=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4NvztpMKDA","classificationName":"coretechnology"},{"depth":0,"name":"Target Customer","queryString":"targetcustomer=undefined","classificationName":"targetcustomer"},{"depth":1,"name":"Healthcare & Life Sciences","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA","classificationName":"targetcustomer"},{"depth":2,"name":"Life Sciences","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA","classificationName":"targetcustomer"},{"depth":3,"name":"Pharmaceuticals","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Kv1pZ8LDA","classificationName":"targetcustomer"}],"classificationDelimited":["TechnologyClassificationModel>Biologicals#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEJDA>Genes#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4NvztpMKDA","SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA>Pharma & Medical Biotechnology#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA","SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA>Pharma & Medical Biotechnology#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA>Drugs Discovery & Development#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Iety_cIDA","IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA>Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA","IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA","IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA>Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA>Pharmaceuticals#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Kv1pZ8LDA","TechnologyClassificationModel>Biologicals#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEJDA","SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA"],"classificationsViewModel":"|0:>TechnologyClassificationModel|1:>TechnologyClassificationModel/Biologicals#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEJDA|2:>TechnologyClassificationModel>Biologicals#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEJDA/Genes#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4NvztpMKDA|0:>SectorClassificationModel|1:>SectorClassificationModel/Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA|2:>SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA/Pharma & Medical Biotechnology#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA|3:>SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA>Pharma & Medical Biotechnology#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA/Drugs Discovery & Development#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Iety_cIDA|0:>IndustryClassificationModel|1:>IndustryClassificationModel/Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA|2:>IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA/Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA|3:>IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA>Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA/Pharmaceuticals#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Kv1pZ8LDA|","classificationTrees":{"sector":[{"title":"Health Tech & Life Sciences","key":"0-0","path":"SectorClassificationModel>Health Tech & Life Sciences","children":[{"title":"Pharma & Medical Biotechnology","key":"0-0-0","path":"SectorClassificationModel>Health Tech & Life Sciences>Pharma & Medical Biotechnology","children":[{"title":"Drugs Discovery & Development","key":"0-0-0-0","path":"SectorClassificationModel>Health Tech & Life Sciences>Pharma & Medical Biotechnology>Drugs Discovery & Development"}]}]}],"targetCustomer":[{"title":"Healthcare & Life Sciences","key":"0-0","path":"IndustryClassificationModel>Healthcare & Life Sciences","children":[{"title":"Life Sciences","key":"0-0-0","path":"IndustryClassificationModel>Healthcare & Life Sciences>Life Sciences","children":[{"title":"Pharmaceuticals","key":"0-0-0-0","path":"IndustryClassificationModel>Healthcare & Life Sciences>Life Sciences>Pharmaceuticals"}]}]}],"coreTechnology":[{"title":"Biologicals","key":"0-0","path":"TechnologyClassificationModel>Biologicals","children":[{"title":"Genes","key":"0-0-0","path":"TechnologyClassificationModel>Biologicals>Genes"}]}]},"sectorClassifications":[{"depth":0,"name":"Sector","queryString":"sectorclassification=undefined","classificationName":"sectorclassification"},{"depth":1,"name":"Health Tech & Life Sciences","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA","classificationName":"sectorclassification"},{"depth":2,"name":"Pharma & Medical Biotechnology","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA","classificationName":"sectorclassification"},{"depth":3,"name":"Drugs Discovery & Development","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Iety_cIDA","classificationName":"sectorclassification"}],"coreTechnologyClassifications":[{"depth":0,"name":"Core Technology","queryString":"coretechnology=undefined","classificationName":"coretechnology"},{"depth":1,"name":"Biologicals","queryString":"coretechnology=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEJDA","classificationName":"coretechnology"},{"depth":2,"name":"Genes","queryString":"coretechnology=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4NvztpMKDA","classificationName":"coretechnology"}],"targetCustomerClassifications":[{"depth":0,"name":"Target Customer","queryString":"targetcustomer=undefined","classificationName":"targetcustomer"},{"depth":1,"name":"Healthcare & Life Sciences","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA","classificationName":"targetcustomer"},{"depth":2,"name":"Life Sciences","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA","classificationName":"targetcustomer"},{"depth":3,"name":"Pharmaceuticals","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Kv1pZ8LDA","classificationName":"targetcustomer"}],"classificationNames":{"sector":["Health Tech & Life Sciences","Pharma & Medical Biotechnology","Drugs Discovery & Development"],"coreTechnology":["Biologicals","Genes"],"targetCustomer":["Healthcare & Life Sciences","Life Sciences","Pharmaceuticals"]},"section":null,"sectionParams":"","queryParams":"","popup_claim_profile":"false","claimedBadge":"inline","display":{"mainContact":"none","climateTag":"none","seeMoreSimilarCompanisDisplay":"none","similarCompaniesTitleFontSize":"3.2rem","similarCompaniesTitle":"Similar Companies","similar_companies":[]},"mainContact":{},"_eventview":{"publicoffering_exit":[{"id":"9xPfYUoUUCAAX6BWz2h6ts8UrKblOIJEJQt4mnfUIV7AGN0WY2NtOq","date":"Sep 2025","amount":"Undisclosed","source":"https://www.tipranks.com/news/company-announcements/silexion-therapeutics-announces-6m-public-offering#google_vignette","ticker":"SLXN","eventtype":"POEvent","valuation":"Undisclosed","investment":[],"capitalraised":"$6M","stockexchange":"NASDAQ","eventvisibility":"Public","amountvisibility":null,"fundingvisibility":null,"stockexchange_key":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgOCIutD_CQw","stockexchange_logokey":"$AU2PTNC6m8YQhSAZinm36kCeLZigl0lwDvuFvOK4ns8LMZtmlmhlUB","style":"","hiddenCompanyTooltip":"","stockexchange_logourl":"https://storage.googleapis.com/clean-finder-353810/$AU2PTNC6m8YQhSAZinm36kCeLZigl0lwDvuFvOK4ns8LMZtmlmhlUB","exit_label":"","po_label":"Public Offering","acquireddesc":"Was acquired by","sectionname":"Public Offerings & Exit","amountnumber":null,"capitalraisednumber":6000000,"valuationnumber":null},{"id":"Y6gHLMgs4DT5Uzf9jsBAohaUCMwrGw9xjtG5goxFbv4sGlx85NyZCa","date":"Aug 2024","amount":"Undisclosed","source":"https://www.globenewswire.com/news-release/2024/08/15/2931245/0/en/Silexion-Therapeutics-Ltd-and-Moringa-Acquisition-Corp-Announce-Closing-of-their-Business-Combination.html","ticker":"SLXN","eventtype":"SpacEvent","valuation":"Undisclosed","investment":[],"capitalraised":"Undisclosed","stockexchange":"NASDAQ","eventvisibility":"Public","amountvisibility":null,"fundingvisibility":null,"stockexchange_key":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgOCIutD_CQw","acquiredcompany_spac":"Moringa Acquisition Corp","stockexchange_logokey":"$AU2PTNC6m8YQhSAZinm36kCeLZigl0lwDvuFvOK4ns8LMZtmlmhlUB","acquiredcompany_spac_id":"jMHxZavYLrxVUxYYBB6QnAeVmnqi3yNQbv7xZBx51gHnRxw93L6Ph5","acquiredcompany_spac_type":"Multinational","acquiredcompany_spac_hidden":true,"acquiredcompany_spac_fullurl":"/mnc_page/moringa-acquisition-corp","acquiredcompany_spac_logokey":"$212EvMfP9e1cXfqQiWj4bR3fCbKPoAcxCMR2DSCYMaj01VANjJEkf7.png","acquiredcompany_spac_urlname":"/mnc_page/moringa-acquisition-corp","acquiredcompany_spac_homepage":"https://www.moringaac.com/","style":"","hiddenCompanyTooltip":"","stockexchange_logourl":"https://storage.googleapis.com/clean-finder-353810/$AU2PTNC6m8YQhSAZinm36kCeLZigl0lwDvuFvOK4ns8LMZtmlmhlUB","acquiredcompany_spac_logourl":"https://storage.googleapis.com/clean-finder-353810/$212EvMfP9e1cXfqQiWj4bR3fCbKPoAcxCMR2DSCYMaj01VANjJEkf7.png","exit_label":"EXIT","po_label":"Initial Public Offering","acquireddesc":"Was acquired by","sectionname":"Public Offerings & Exit","amountnumber":null,"capitalraisednumber":0,"valuationnumber":0}],"privateequityfunding":[{"id":"lALX6gpmNteKlie7QZEc6xotFcAZQ3PJvDIgjl1OzCREa2NTob1qus","date":"Jan 2025","amount":"$3.3M","source":"https://www.globenewswire.com/news-release/2025/01/29/3017648/0/en/Silexion-Therapeutics-Announces-Exercise-of-Warrants-for-3-3-Million-Gross-Proceeds.html","eventtype":"FundingRoundEvent","investment":[],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"PIPE","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","sectionname":"Private Equity Funding","amountnumber":3300000,"capitalraised":"Undisclosed","valuation":"Undisclosed"},{"id":"KyxWG62jhxMOt1IWqJBqz1YXhZbR2JdX7gdSp0UgL66LmLblxyKlKM","date":"Oct 2015","amount":"$2.35M","source":"pitchbook","eventtype":"FundingRoundEvent","investment":[{"name":"Esperante Ventures","type":"Investor","amount":null,"hidden":false,"country":"Netherlands","fullurl":"/investor_page/esperante-ventures","logokey":"$ecItkh2OXcAwDfS5y9qbsBxjwnoKV9ipUEAeAZBUo7tCOH2acuvhiC","tagline":"","urlname":"/investor_page/esperante-ventures","isisraeli":0,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgOD4u4ShCgw","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"rDORLUF6UUD5v51moaPghp0eufQNOQBmUFnIUzFGec0pfrbWV5YhU2","fundingsubtype":"VC and Private Equity","investorislead":1,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":1,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$ecItkh2OXcAwDfS5y9qbsBxjwnoKV9ipUEAeAZBUo7tCOH2acuvhiC","leadcaption":"Lead ","followupcaption":"Follow on "}],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"Undisclosed Round","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","sectionname":"Private Equity Funding","amountnumber":2350000,"capitalraised":"Undisclosed","valuation":"Undisclosed"},{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgODO_sKOCAw","date":"Apr 2014","amount":"$10M","source":"https://www.esperanteventures.com/portfolio/silenseed/","eventtype":"FundingRoundEvent","investment":[{"name":"Esperante Ventures","type":"Investor","amount":0,"hidden":false,"country":"Netherlands","fullurl":"/investor_page/esperante-ventures","logokey":"$ecItkh2OXcAwDfS5y9qbsBxjwnoKV9ipUEAeAZBUo7tCOH2acuvhiC","tagline":"","urlname":"/investor_page/esperante-ventures","isisraeli":0,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgOD4u4ShCgw","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"aca945b4-f09e-46b9-bfca-32d296b3ca67","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$ecItkh2OXcAwDfS5y9qbsBxjwnoKV9ipUEAeAZBUo7tCOH2acuvhiC","leadcaption":"","followupcaption":""}],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"Seed","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","sectionname":"Private Equity Funding","amountnumber":10000000,"capitalraised":"Undisclosed","valuation":"Undisclosed"}],"nonequityfunding":[{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgOCutMbTCAw","date":"Sep 2009","amount":"$6M","source":"https://www.sec.gov/Archives/edgar/data/1602634/000117891314002077/exhibit_10-6.htm","eventtype":"GrantEvent","granttype":1,"investment":[],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":null,"isjointventuregrant":0,"fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","sectionname":"Non-Equity Funding","isgrant":true,"isicoevent":false,"amountnumber":6000000,"capitalraised":"Undisclosed","valuation":"Undisclosed"}],"merger_acquisitions":[],"others":[]}}